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Abstract 
 
A major challenge in neuroscience research is to dissect the circuits that orchestrate 
behavior in health and disease. Proteins from a wide range of non-mammalian 
species, such as microbial opsins, have been successfully transplanted to specific 
neuronal targets to override their natural communication patterns. The goal of our work 
is to manipulate synaptic communication in a manner that closely incorporates the 
functional intricacies of synapses by preserving temporal encoding (i.e. the firing 
pattern of the presynaptic neuron) and connectivity (i.e. target specific synapses rather 
than specific neurons). Our strategy to achieve this goal builds on the use of non-
mammalian transplants to create a synthetic synapse. The mode of modulation comes 
from pre-synaptic uptake of a synthetic neurotransmitter (SN) into synaptic vesicles by 
means of a genetically targeted transporter selective for the SN. Upon natural 
vesicular release, exposure of the SN to the synaptic cleft will modify the post-synaptic 
potential through an orthogonal ligand gated ion channel. To achieve this goal we have 
functionally characterized a mixed cationic methionine-gated ion channel from 
Arabidopsis thaliana, designed a method to functionally characterize a synthetic 
transporter in isolated synaptic vesicles without the need for transgenic animals, 
identified and extracted multiple prokaryotic uptake systems that are substrate specific 
for methionine (Met), and established a primary/cell line co-culture system that would 
allow future combinatorial testing of this orthogonal  transmitter-transporter-channel 
trifecta.    
Synthetic synapses will provide a unique opportunity to manipulate synaptic 
communication while maintaining the electrophysiological integrity of the pre-synaptic 
cell. In this way, information may be preserved that was generated in upstream circuits 
and that could be essential for concerted function and information processing. 
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Introduction 
 
The mammalian central nervous system is one of the most complex maps on which 
information flow exists, even if compared to the Internet, which is the largest computer 
network established to date and currently consists of close to two billion websites [1]. 
In comparison, the number of neurons in canonical mammalian model systems used 
in research ranges from 30 million (in mice) to 100 billion (in humans) [2] with each 
neuron making upwards of a thousand synaptic connections [3]. This degree of 
complexity at the single neuron level translated en masse reveals a connectivity map 
with trillions of nodes. 
The analysis of neuronal connections and their role in a specific animal 
behavior has been one of the defining aspects in our understanding of higher cognitive 
functions for more than a century [4] and yet today researchers are still disentangling 
neuronal connectivity, both morphologically and functionally. The ebb and flow of 
information transfer in the mammalian brain is sometimes paraphrased as a repeated 
analog-to-digital conversion [5, 6]. This conversion, which has been observed in the 
visual system, the hippocampus and neocortex of rodents [7-9], is one of the hallmarks 
of complexity in the mammalian brain and a result of the interplay of multi-tiered 
regulatory elements, such as gene activation or suppression, protein regulation and 
activation, signaling cascades, and cell-cell type interactions [10-15]. A macroscopic 
example of this conversion is the concept of convergence, in which many pre-synaptic 
digital outputs translate to many post-synaptic analog inputs, all of which are computed 
to a singular digital output (firing or no firing) of the post-synaptic cell [16]. It is the 
combination of multiple inputs in time and space that allows information to be passed 
on in a manner that is modulated by upstream regulation. The breakdown of this 
computation process can have devastating effects, and often because of its 
fundamental role in physiology results in neurological diseases, such as motor 
dysfunction (e.g. Parkinson’s [17, 18], Huntington’s  [19-22], disease), inhibitory 
dysfunction (e.g. autism spectrum disorder [23]), and memory loss (e.g. Alzheimer’s 
disease [24-26]). 
To understand the significance of activity in individual connections mapping of 
inputs and outputs in the intact tissue is a prerequisite. Great strides have been made 
through the use of advanced genetic strategies including Brainbow [27, 28], imaging, 
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high throughput EM [29], and viral tracers [30, 31] to understand cell type connectivity 
within and across brain regions. Yet, our understanding of the functional relevance of 
the mammalian brain connectome is far from complete [32] and there is an ongoing 
need for new methods to allow finer functional control over morphologically defined 
connections.  
The introduction of exogenous electrical signals into excitable cells, either 
electrically (e.g. using electrodes) or remotely (as explained below) is a powerful form 
of manipulation towards elucidating determinates of information flow in the nervous 
system and has historically been the method of choice. Many modern implementations 
incorporate biological tools in intact circuits via genetic perturbation that have been 
designed to exert control over defined cellular populations. The move from in vitro 
studies to the intact organ in behaving animals posed new challenges in the 
application of these techniques, such as the difficulty to alter neuronal behavior in a 
targeted fashion. These challenges have been successfully met with the genetic 
introduction of various tools, most notably, optogenetics [33, 34] and chemogenetics 
[35, 36]. However, the current toolbox that allows for a causal relationship between 
cell type and behavior employs a brute force induction that is often binary. Thus new 
methodology that reflects the non-linearity of information flow by mimicking analog-
like responses may become an important new approach to our understanding of brain 
function in health and disease. 
This work focused on the design of new biological tools and methods that will 
help to dissect neuronal connections and their impact on organism behavior by 
targeting the neuronal analog-to-digital conversion. This goal was achieved by 
hypothesizing a synthetic neurotransmission (SNT) system that preserves upstream 
information while simultaneously manipulating the computation of the post-synaptic 
target (chapter 1), characterizing a methionine-gated cation channel as a candidate 
for the SNT receptor (chapter 2), permeable to Ca2+ as a chemogenetic tool that can 
be tuned for graded bioelectrical responses in mammalian cells, and developing a new 
method to understand the relationship of proteins involved in pre-synaptic release in 
chemical transmission by altering protein content in isolated synaptic vesicles in vitro 
(chapter 3). This work furthermore addresses future experimental designs to test the 
pre-synaptic incorporation for a synaptically selective post-synaptic override method 
(chapter 4).  
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Chapter 1: Synthetic Neurotransmission: 
Manipulating Neuronal Communication with 
Intrinsic Encoding and Connectivity 
 
This chapter is a hypothesis manuscript in preparation (Catherine McKenzie and 
Harald Janovjak, 2018). 
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1.1. Abstract 
A major challenge in neuroscience research is to dissect the circuits that orchestrate 
behavior in health and disease. Here, we hypothesize that this challenge may be 
tackled by extending current concepts and existing methodologies with a synthetic 
neurotransmission (SNT) system. Specifically, we propose a synthetic 
neurotransmitter that will be taken up and loaded into pre-synaptic vesicles that have 
been genetically-modified with new and orthogonal membrane transporters. Upon 
vesicle release triggered by the natural firing pattern of the neuron, the synthetic 
neurotransmitter will activate specific post-synaptic neurons that synaptically express 
a new and orthogonal receptor. Because of the necessity of introduced transporters 
and receptor, SNT will allow targeting of selected synapses in a circuit and in addition 
exploit endogenous firing patterns for modulation of neuronal activity. This approach 
is thus complementary to light-activated ion channels and orthogonal ligand-receptor-
pairs, which target selected neurons and override their natural activity patterns. In this 
hypothesis article, we describe the motivation for developing SNT, explain the possible 
strategies to experimentally realize it and speculate how SNT will open new research 
avenues for decoding neural circuits, understanding of the intricacies of synaptic 
communication and developing disease models 
 
 
1.2. Hypothesis 
The development and function of all multicellular organisms relies on ordered 
communication of cells. The nervous system offers a prime example for the 
importance of ordered cell-cell communication that has been extensively investigated 
throughout the last three centuries. The concept of synapses (Greek: synapsis - 
junction) emerged at the end of the nineteenth century when Santiago Ramón y Cajal 
predicted synapses as “contacts at the level of certain apparatus or dispositions of 
mechanisms, whose objective is to establish connection” [37]. The term ‘synapse‘ was 
coined by Charles Scott Sherrington in 1897 at a time where the prevailing theory for 
interneuronal communication was based on electrical signals [38]. Two ground 
breaking hypotheses, the chemical nature of communication and the existence of 
specific receptors for chemical agents, revolutionized our view of neuronal 
communication at the turn of the century [39, 40]. With the advent of chemical 
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synthesis, genetics and molecular biology, the twentieth century led to the 
identification and characterization of components fundamental in synaptic 
communication. Acetylcholine was the first chemical neurotransmitter to be 
synthesized, and it was shown to activate cells about sixty years before the genetic 
identity of acetylcholine receptors was revealed [41-43]. The discovery of acetylcholine 
was followed by the discovery of GABA, serotonin, glutamate, dopamine and glycine 
within the 1950s and 60s [44-48]. While the components driving many aspects of 
neuronal communication have been demystified in the past two centuries, one on-
going challenge in this century is to discover how they orchestrate activity in health 
and disease. Here, we hypothesize that we may tackle this challenge by extending 
current concepts and existing methodologies with a synthetic neurotransmission 
(SNT) system that operates orthogonally to normal neuronal communication. 
Relaying the correct information from one area of the nervous system to 
another requires synapses working en masse. In the typical mode of synaptic 
communication, electrical spiking in the axon of the pre-synaptic neuron results in 
neurotransmitter release from pre-synaptic vesicles and activation of receptors on the 
post-synaptic cell (Fig 1.1A). Disruption of connectivity leads to serious behavioral 
malfunctions observed in neurological diseases, which has had the positive side effect 
that scientists were inspired to create new methods to enhance or reduce neuronal 
activity. The birth of many recent methods to manipulate neurons coincided with the 
emergence of synthetic biology in the neurosciences. Highlights of synthetic biology 
contributions are the repurposing of naturally-occurring opsins [33], such as 
channelrhodopsin from C. rheinhardtii, and the engineering of semi-chemical systems 
[49], for the optical actuation or inhibition of neuronal firing. The light-sensitive proteins 
are complemented by ‘orthogonal’ receptors designed to be sensitive to non-natural 
ligands [50-52] (Fig 1.1B), each of which are masterpieces of protein engineering. 
Paired with advancement in genetic targeting to selected neuronal populations, these 
methods allowed scientists to gain unparalleled access to the inner workings of the 
nervous system in many model organisms. In particular, optical manipulation of 
genetically-selected neurons with high spatial (micrometers to centimeters) and 
temporal (milliseconds to minutes) has allowed deciphering the necessity of subtype 
specific signals, i.e. interneurons, and delving into behavior linked to specific neurons 
within a circuit. 
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Fig 1.1. Modulating a synapse with a synthetic neurotransmitter Comparison of 
(A) native synaptic transmission, (B) orthogonal receptor-ligand-pairs [50-52], (C) false 
neurotransmitters [53, 54], and (D) SNT that is proposed here. The synthetic 
neurotransmitter is only taken up by cells that express new transporters. Also, the 
synthetic neurotransmitter selectively activates cells that express a new ligand-gated 
ion channel. Thus only selected synapses are modulated by SNT . 
 
 
Currently it is not feasible to manipulate neuronal communication in a manner that 
closely incorporates the functional intricacies of synapses. For instance, activation or 
inhibition by light and orthogonal ligands imposes firing patterns and selects synapses 
in manner that is limited by the fidelity of spatially-confined illumination or diffusion. To 
complement the existing methodological arsenal, we propose to develop methods that 
on one hand allow experimenters to intervene with neuronal connections from the 
outside, as with the tools described above, while preserving encoding and 
connectivity. Specifically, we hypothesize that this may be achieved by creating a 
synthetic neurotransmitter, which we define as a non-native small molecule that 
produces additional post-synaptic responses upon pre-synaptic vesicular release. The 
synthetic neurotransmitter could be added to systems in vitro or in vivo, e.g. by 
systemic injection, at the time that manipulation is desired, yet would exclusively 
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function at selected synapses between cells that were ‘sensitized’ (Fig 1.1D). 
Sensitization of the pre-synaptic cell will be achieved by expression of transporters 
engineered for uptake and release of the synthetic neurotransmitter. Sensitization of 
the post-synaptic cell will be achieved by expression of an ionotropic receptor 
engineered to be selectively activated by the synthetic neurotransmitter. Because 
synthetic neurotransmitters act as neurotransmitters only at synapses between cells 
that were genetically-modified they may enable many new types of experiments (see 
below). This idea extends the concept of ‘false neurotransmitters’, which also are non-
natural small molecules packaged into synaptic vesicles (Fig 1.1C) but serve to 
visualize vesicle fusion or activate selected endogenous post-synaptic targets [53, 54]. 
Already in 1993, Jahr and co-workers demonstrated the principle of false 
neurotransmitter signaling at glutamatergic synapses (Pan et al, 1993), but very few 
studies followed up on this clever approach, with one elegant example being the false 
fluorescent neurotransmitters at dopamine synapses [54]. 
Which new experiments will be enabled by SNT? First, SNT may aid in 
deciphering of neural circuits. The technique will impart the ability to modulate specific 
neural connections because it effectively targets synapses rather than neurons. In 
principle, all synapses of a connection may be targeted because modulation is 
generated intrinsically and may be applicable also in those cases where selection of 
projections by confined illumination is not possible. Second, synthetic 
neurotransmission may shed new light on the many fundamental processes that are 
controlled by temporal activity and vesicular release patterns, such as synaptic 
plasticity or dendritic integration. New experiments will be enabled because the 
technique will preserve firing patterns in the pre-synaptic cell and modulate the post-
synaptic signal in strength based on this intrinsic pattern. In this way information may 
be preserved that was generated in upstream circuits and that could be essential for 
concerted function and information processing. In complementary experiments, it 
should also be possible to introduce the ligand-gated ion channel into pre-synaptic 
cells and use the synthetic neurotransmitter as a retrograde messenger. Third, taking 
advantage of the preservation of temporal firing patterns, SNT may lead to the 
development of models of disease and drug action, because in both cases gradual 
modulation of synaptic communication is imparted. 
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We have entertained three paths to realizing SNT in the mammalian nervous 
system. First, mammalian ligand-gated ion channels and neurotransmitter 
transporters may be reengineered through mutagenesis to interact with a molecule 
that is otherwise inert for the neuronal signaling machinery. This molecule may then, 
preferably after passing the blood brain barrier, act as the synthetic neurotransmitter 
between cells modified with the engineered ligand-gated ion channel and transporters. 
Indeed, altering binding specificity of receptors through mutagenesis was successful 
in the past for ligand-gated ion channels and G-protein coupled receptors [50-52]. 
However, the encouragement that this past work provides is mild because the 
chemical and genetic space that needs to be sampled during engineering is 
substantial and because less precedence exists for engineering of membrane 
transporters. Second, an entire mammalian neurotransmission machinery, consisting 
of the neurotransmitter, ligand-gated ion channel and transporters, may be introduced 
into brain regions where it normally is not found. Although this appears to be a 
straightforward approach our analysis of the mouse brain suggest that likely all major 
brain regions are innervated by most if not all neurotransmitters, which reflects that 
the nervous system is efficient at employing a relatively short list of messenger 
molecules. This approach thus may be limited in terms of orthogonality, flexibility and 
reliability. Third, a set of non-mammalian proteins, including ligand-gated ion channel 
and transporters, may be transferred to the mammalian brain. In this way the design 
of matching binding sites can be ‘outsourced’ to Nature based on the hypothesis that 
the diverse habitats of various species have produced proteins responsive to ligands 
not found or not used in the mammalian nervous system [55, 56]. This approach 
removes the need for binding site engineering but requires that a ligand-gated ion 
channel and transporters for the same molecule can be identified and expressed 
functionally in mammalian neurons. Interestingly, the light-driven proton pump Arch 
was recently targeted into neuron vesicles [57], and this work demonstrates that 
mammalian vesicles can be ‘functionalized’ with a non-mammalian membrane protein. 
Finally, a combination of the second and third approach may be envisioned, e.g. based 
on dopamine-gated ion channels [58]. Notably, all three approaches discussed above 
benefit from many of the techniques that already enabled the success of synthetic 
neurobiology, such as viral vectors, Cre-dependent expression or de novo synthesis 
of mammalian codon-optimized genes. 
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To summarize, we conclude that SNT may become a valuable asset for the 
understanding of nervous system function on several levels ranging from microcircuits 
to in vivo behavior and that its technical realization may be may be possible, an effort 
we believe is worth pursuing.  
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Chapter 2: Repurposing a Methionine-gated 
Ionotropic Receptor for Orthogonal Control of 
Bioelectrical Activity in Mammalian Cells 
 
I would like to thank Marco Stadler (Department of Pharmacology and Toxicology, 
University of Vienna) who performed all oocyte experiments and Daniel Tapken (Ruhr 
University Bochum) for the AtGLR1.4 pore point mutation as well as numerous insights 
into AtGLRs. I would also like to thank Giulio Abagnale for his assistance with STED 
imaging, Ben Suter and Alexander Johnson for their insights on image analysis, and 
Yoav Ben-Simon who performed viral injections, subsequent perfusion, slice, and 
mounting. In addition, I would like to thank Dr. Ryuichi Shigemoto for the custom GluA2 
antibody. This chapter is a research manuscript in preparation (Catherine McKenzie, 
Daniel Tapken, Marco Stadler, Yoav Ben-Simon, Giulio Abagnale, and Harald 
Janovjak). 
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2.1. Abstract 
Understanding the significance of cellular and subcellular communication between and 
among neuronal circuits is a fundamental goal in bridging the gap between the tangible 
elements of the brain and behavior of an organism.  The biological toolbox that has 
been developed to override communication has in recent years incorporated 
genetically targeted designer receptor-ligand pairs referred to as chemogenetics, 
which allows specified modulation of cell-type specific behavior upon activation of a 
synthetically derived ligand.  Here we have identified and expressed a modified plant 
glutamate-like receptor, iMetR in HEK 293 cells and neurons as a way to modulate 
bioelectric activity in mammalian cells by making use of its evolutionarily derived 
“designer” ligand, methionine and calcium permeable mixed cationic pore conducting 
properties. Taking advantage of its analogous secondary structure to ionotropic 
glutamate receptors we were able to target variants of iMetR subcellularly and show 
that methionine application in mammalian cells that express iMetR or variants induce 
bioelectric signals in a synthetic manner.   
 
 
2.2. Introduction 
Decoding the roles of specific neuronal and non-neuronal cell types in complex 
behaviors and physiological processes is fundamental to our understanding of brain 
function in health and disease. ‘Synthetic’ perturbation of electrical signals by means 
of introduced receptors and ion channels has proven to be an invaluable approach to 
examine the link between cellular activity and organism function. The current toolbox 
consists of designer receptors that are classified by their cognate actuators, which are 
either photons (in optogenetics) or chemicals (in chemogenetics). Specifically, 
optogenetic and chemogenetic receptors engineered to respond to light or highly 
selective ‘designer’ molecules have enabled researchers to resolve the key 
determinates that underlie observable behaviors in vivo, such as taste differentiation, 
hunger and pleasure states, as well as memory encoding [33, 59-62]. Ion channels 
are particularly well suited for this purpose because they create additional ion fluxes 
that augment or override native physiological electrical activity states. The channels 
can be selected or engineered for characteristic depolarizing or hyperpolarizing 
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conductances [63, 64] to ultimately direct cell behavior in defined spatial and temporal 
locations. 
Chemogenetic tools for neuronal manipulation have in the past been based on 
ligand-gated ion channels (LGICs) [50, 64] and G-protein coupled receptors (GPCRs) 
[51, 52, 65, 66]. In their most advanced form, these proteins are synthetically altered 
to attenuate native ligand reactivity while exhibiting sensitivity to a novel ligand. All of 
the current tools rely on redesign of a native protein in conjunction with the use of a 
synthetic agonist [50, 52, 64]. Whereas these designs have been successful they can 
be accompanied by limitations, such as lack of blood brain barrier (BBB) permeability 
[67], incomplete orthogonality [64], reliance on second messenger pathways [51, 52], 
need for heteromeric subunit assembly [64], and potentially unsought interactions with 
endogenous proteins. A desirable alternative to synthetic orthogonality would be to 
take advantage of the evolutionary lineage of LGICs. Identifying homologs that retain 
neuronal modulation properties, such as the desired ionic selectivity, yet disclude 
orthogonality issues, such as activation by native molecules, may be a complementary 
and potent alternative. Here, we hypothesized that plant glutamate-like receptors 
(GLRs) carry many of the attributes of an ideal receptor-ligand pair. 
Ionotropic GluRs (iGluRs) are specialized mammalian GLRs that are 
irreversibly intertwined in the computation of cells involved in cognitive processes like 
learning and memory, as well as homeostatic regulation/innate physiology [68]. iGluRs 
are mixed cation permeable (of physiological relevance are Na+ and K+ and finely 
tuned additional Ca+2 permeabilities) and cluster post-synaptic loci to mediate 
excitatory ionic conductance. Due to the nature of iGluRs and their pivotal roles in 
electrical-activity driven systems, the discovery of GLRs in plants (e.g., AtGLRs in the 
important model plant A. thaliana) was unforeseen but fortuitous. AtGLRs have similar 
ionic preferences to iGluRs [69-71] that makes them potential candidates for 
chemogenetic tools if orthogonality in ligand binding is intrinsic or can be introduced. 
The family of AtGLRs diverges into three clades exhibiting conserved structural 
topology with the mammalian glutamate receptors (GluRs) [63, 72]. AtGLR1.4, a 
member of clade 1, has been well-characterized in both structure and function [63]. 
Notably, the ligand binding domain of AtGLR1.4 has no potency for glutamate or many 
of the major neurotransmitters in the mammalian central nervous system (CNS) [63], 
but rather is a methionine-gated, Ca+2 permeable mixed cation channel [63]. Met is an 
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essential amino acid that plays multiple key roles in mammalian metabolism but does 
not activate mammalian receptor proteins. Prior uses in humans as a dietary 
supplement, as an antidote or in CNS cancer imaging indicate a safe and well known 
pharmacological profile making it suitable as a designer ligand.  
Here, we show that an optimized variant of AtGLR1.4, termed iMetR, expresses 
well in a number of expression systems and neurons, both ex and in vivo. This channel 
shows detectable current when its agonist Met is applied and can be blocked by its 
natural antagonist arginine (Arg). Combined, this translates to a chemogenetic “on/off” 
switch for bioelectric activity in mammalian cells. In addition, ligand profiling revealed 
the ability to remotely switch activation states in a graded fashion, by tuning Met 
concentrations in a simulated in vivo environment. In this chapter, we present the first 
example of the functional expression of a clade 1 plant glutamate-like receptor in 
mammalian cells, paving the way for future repurposing for neuronal modulation. As 
outlined in chapter 4, endogenous and exogenous Met transport systems exist and 
AtGLR1.4 may be combined with those to achieve synthetic neurotransmission (SNT) 
relying on its graded response to Met in antagonistic-containing buffers. 
 
 
2.3. Methods 
2.2.1. Animals 
All animal experiments were performed in strict accordance with institutional, national, 
and European guidelines for animal experimentation and were approved by the 
Bundesministerium für Wissenschaft, Forschung und Wirtschaft of Austria (A. 
Haslinger, Vienna; BMWFW-66.018/0007-WF/II/3b/2014)  
8 week old C57BL/6J mice were put under light anesthesia via isoflurane and placed 
into a head fixed stereotaxic frame (RWD Life Science). Animals were kept under 
anesthesia with a continuous flow of 1-3% vaporized isoflurane, mixed with 100% O2 
at a flow rate of 0.5 L/min. Incision was made front to back to expose the skull and the 
bregma was located. Two small holes were drilled above the dorsal dentate gyrus 
(DG) bilaterally and the durum was gently removed. 0.5 µL concentrated lenti virus 
(see below) was injected bilaterally at a rate of 100 nL/min using a syringe (Hamilton) 
fixed with a 33G needle into the dorsal DG at coordinates ±1.5 mm medial/lateral, 1.8 
mm anterior/posterior, 1.9 mm dorsal/ventral from the bregma. Animals were kept in 
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their home cage with ad lib water and food for 2 weeks. Mice were perfused with 15 
mL phosphate buffer (0.1M Na2HPO4 and 0.1M NaH2PO4 titrated to pH 7.35) followed 
by 15 mL 4% paraformaldehyde (PFA). Fixed brains were sectioned coronally at a 
thickness of 100 μm using a Leica VT1200S vibratome. Slices were mounted on micro 
slides (Assistant) with Mowiol mounting media (6 g glycerol, 2.4 g Mowiol® 4-88, 12 
mL 0.2 M Tris-HCl) and covered by 0.15 mm glass coverslips.  
 
2.2.2 DNA constructs 
pSGEM::AtGLR1.4, pSGEM::AtGLR1.4(C610W), and pSGEM::GluA2(Q)flop(L483Y) 
vectors were a generous gift from Daniel Tapken(RUHR University BOCHUM). 
Stargazin (ɣ2) vector was a generous gift from Daniel Choquet (University of 
Bordeaux). GluA2(flop)_eGFP was a generous gift from Maximilian Ulbrich (University 
Freiburg) and mVenus was a generous gift from Richard Tsien (New York University).  
iMetR1.0, a variant of AtGLR1.4 (Uniprot-ID Q8LGN1) was modified for mammalian 
expression, adapted from previous work on iGluRs and opsins [49, 73]. Applying 
conventional cloning strategies, AtGLR1.4 was extracted from 
pSGEM::AtGLR1.4_eYFP by Polymerase Chain Reaction (PCR) and subcloned into 
a modified mammalian expression vector driven by the human cytomegalovirus (CMV) 
promoter (pcDNA3.1(-), Invitrogen/Life Technologies). The modified vector contained 
a membrane trafficking signal (VNIKSRITSEGEYIPLDQID, Addgene 26966), eYFP 
(Addgene 26966), and ER export signal (KFCYENEV, Addgene 26966) for enhanced 
receptor trafficking and membrane expression followed by a WPR element [49] after 
the stop codon. In the resulting construct, the AtGLR1.4 signal peptide (SP) (amino 
acids 1-29) was exchanged for the neuronal nicotinic acetylcholine receptor β subunit 
(βnAchR) SP (amino acids 1-18, GenBank: CAA33839.1, [74]. A mutation from 
cysteine (C) to tryptophan (W) in AtGLR1.4 at position 610 (, designed to increase 
channel conductance, was identified by Daniel Tapken (Hollmann lab, RUHR 
University BOCHUM) and was introduced into iMetR1.0 at position 599 as well as 
mutations to Alanine, Serine, or Tyrosine through site-directed mutagenesis [75]. 
iMetR1.0ΔC599W was mammalian codon optimized according to the supplier’s 
recommendation (Epoch Life Sciences) with an additional AgeI site introduced at 
position (874-5) directly after the Kv1.2 membrane trafficking signal. An mVenus 
amplified by PCR and inserted into the Age1 site and the resulting construct renamed 
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iMetR. C-terminal variants iMetRΔR2ct and iMetRγ215 were designed by introducing 
an AgeI (iMetRγ215), or replacing the entire AtGLR1.4 C-terminus (CT) (iMetRΔR2ct, 
811-850) with an AgeI restriction site at position 850 (YLIPWTGKSRITS) into iMetR 
using reverse PCR. A synthesized cDNA fragment (Integrated DNA Technologies) 
corresponding to the CT of GluA2 (R2) (UniProtKB: P19491 GR1A2_RAT) or 
5’phosphorylated ultramers (Integrated DNA Technologies) encoding the PDZ-binding 
motif of Stargazin (ɣ215) (UniProtKB: 088602 CCG2-MOUSE) were subsequently 
subcloned into pcDNA3.1(-)::CMV::iMetR in corresponding places (see above). pCCL 
viral vectors (9765382) containing iMetR, iMetRΔR2ct, and iMetRγ215 between NheI 
and SalI were modified for targeted neuronal expression by swapping a human 
phosphoglycerate kinase (hPGK) promoter for a human synapsin (hSyn) promoter. 
GluA2(flop)_eGFP, AtGLR1.4_eYFP, iMetR and all variants were expressed either 
under the control of CMV promoter for cell line expression or the hSyn promoter for 
neuronal expression. All constructs were verified in frame by sanger sequencing (LGC 
genomics). 
 
2.2.3. HEK 293 cell culture 
For whole cell patch clamp and imaging, HEK 293 cells were seeded in D5 (Dulbecco’s 
modified Eagle’s medium (Life Technologies) supplemented with 5% v/v fetal bovine 
serum (FBS, Life Technologies), at a density of 3.0-8.0 x 104 on poly-L-lysine (PLL) 
coated 12 mm glass coverslips as described previously [76]. Briefly, coverslips (A. 
Hartenstein, 0.17 mm) were prepared by washing once with 100% ethanol followed by 
5 washes with ultrapure water (Life Technologies). Coverslips were further autoclaved 
and dried in an oven (HEREAUS, 120°C for 2h) followed by UV sterilization. Coverslips 
were coated for 1-2 h before plating with PLL (0.1% w/v, Sigma in water) washed once 
with ultrapure water and allowed to dry completely. For imaging, 24-well glass bottom 
plates were treated as above with the exception of autoclaving. Cells were transfected 
at equal molar ratios with lipofectamine 2000 (1mg/mL, Life Technologies) at a 1:1 
(µg/µl) ratio where applicable, in Opti-MEM I medium (Gibco) 18 h after seeding. 
Medium was changed to D5 (electrophysiology) or D10 (Dulbecco’s modified Eagle’s 
medium (Life Technologies) supplemented with 10% v/v FBS, 100 U/ml penicillin and 
0.1 mg/ml streptomycin) (imaging) after 7 h and incubated at 37°C in a 5% CO2 
atmosphere for 48-72 h. For imaging, 24 h after transfection cells were transferred to 
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33°C in a 5% CO2 atmosphere and incubated for another 24-36 h [77]. Cells were 
imaged either in modified tyrode solution (TIRF) (NaCl 150 mM, KCl mM, MgCl2 2 mM, 
CaCl2 2 mM, D-Glucose 10 mM, HEPES 10 mM pH.4) or fixed with 4% PFA (confocal) 
and maintained at 4°C in PBS 0 - 2 d before imaging.  
 
2.2.4. Lenti virus production 
Lenti virus production and purification was performed as described previously [78]. 7.0 
x 106 Lenti-X 293T cells (Clontech) were seeded in D10 in poly-L-ornithine (PLO) 
(0.01% w/v, Sigma) coated 15 cm cell culture dishes (Corning) and incubated at 37°C 
in a 5% CO2 atmosphere. After 15 h, medium was changed and cells were incubated 
at 37°C for 30 min. Cells were then transfected with pccl::hysn:: iMetR or variants of 
MDL and REV (third generation pHelper plasmids), and VSV-G (packaging plasmid) 
at a 1:1:1:1 molecular ratio (total amount: 28 µg per dish) with polyethylenimine (PEI) 
(Polysciences) in Opti-MEM I medium. Medium was changed 7 h after transfection. 
40-48 h after transfection, supernatant was collected for centrifugation at 1,000 x g for 
10 min, and subsequently filtered (0.45 µm). For virus concentration, filtered 
supernatant was layered over a 10% v/v sucrose cushion (20% w/v sucrose in 1 M 
NaCl, 20 mM HEPES, 0.25 mM EDTA, pH 7.4) and centrifuged at 4°C for 1.5 h at 
150,000 x g. During 2 to 4 separate centrifugation runs, pellets were consolidated and 
resuspended in culture medium (see below) and stored at 4°C. After centrifugation, 
concentrated virus was either aliquoted directly or further concentrated with Vivaspin® 
centrifugal concentrator (Vivaproducts) for in vivo applications. Virus was aliquoted 
into O-ring conical tubes, snap frozen and stored at -80°C. Physical titer was 
determined using a reverse transcriptase qPCR kit following the provider’s protocol 
(Genecopia). Each viral preparation was tested for functional expression with a dilution 
series in glass bottom 24-well plates containing 2.5 x 105 cortical neurons/well. After 
5 d, expression was assessed daily using an EVOS FL microscope (Thermo Fisher 
Scientific). The virus concentration that produced the highest expression in 
morphologically healthy cells at day in vitro (DIV) 15 was then utilized for transduction 
of neurons on 12 mm glass coverslips (see below). For in vivo injections titers of 
between 1 x 109 - 1011 viral particles/mL were used.  
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2.2.5. Primary neuronal culture 
Primary dissociated hippocampal neurons were prepared from batches of 2-4 P0-P1 
Wistar rat pups as described previously [76] with modifications as follows. Hippocampi 
were isolated from both hemispheres in dissecting solution (Hank's balanced salt 
solution supplemented with 2.5 mM HEPES, 35 mM D-glucose, 4 mM NaHCO3, pH 
7.4) by removing midbrain, cerebellum and olfactory bulb and clearing the meninges 
from the tissue. Cortical hemispheres were flipped sagittally and hippocampi were 
removed with fine tip forceps and transferred to a 15 mL conical tube filled with 
dissecting solution on ice. Dissociation was carried out using a papain dissociation 
system following the provider’s protocol (Worthington). Neurons were maintained 
following established protocols [79] with modifications. Cells were suspended in 
plating medium that consisted of modified Eagle’s medium (MEM) (Thermo Fisher 
Scientific) supplemented with 10% v/v FBS, 0.6% w/v D-glucose (Sigma), 6 mM 
GlutaMAXTM (Thermo Fisher Scientific), 1 mM Na-pyruvate (Sigma), 100 U/mL 
penicillin and 0.1 mg/mL streptomycin. Cells were counted in a Neubauer chamber 
and 0.5-1.0 x 105 cells were seeded on 12 mm glass coverslips (0.17 mm for 
electrophysiology or 0.15 mm for imaging) as prepared above. After 5 to 6 h, one 
volume of culture medium (Neurobasal-A (Thermo Fisher Scientific), supplemented 
with 2% v/v B27TM (Thermo Fisher Scientific), 6 mM GlutaMAXTM) was added to each 
well. At DIV2 to DIV3, medium was supplemented with 4 µM cytosine β-D-
arabinofuranoside (Sigma) to reduce glial growth. Finally, cells were transduced with 
lenti virus during medium change at DIV5 and subsequently half of the culture medium 
was changed every 2 to 3 d. Neurons were typically transduced with 0.1 µl of 
concentrated virus solution (1.0 x 109 viral particles/mL) and displayed robust 
expression at DIV15.  
 
2.2.6. Electrophysiology 
2.2.6.1. Xenopus laevis oocyte two-microelectrode voltage-clamp experiments 
Preparation of stage V–VI oocytes from Xenopus laevis and synthesis of capped runoff 
poly(A) cRNA transcripts from linearized cDNA templates (pSGEM:: 
pSGEM::AtGlR1.4(C610W) and pSGEM::GluA2(Q)flop(L483)) was synthesized from 
1 μg of linearized template DNA with the mMESSAGE mMACHINE T7 in vitro 
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Transcription Kit (Thermo Fisher Scientific). Preparation of stage V–VI oocytes from 
Xenopus laevis was performed as described elsewhere [80]. Female Xenopus laevis 
frogs were anesthetized by 15 min incubation in a 0.2% MS-222 solution (methane 
sulfonate salt of 3-aminobenzoic acid ethyl ester, Sigma) before removing parts of the 
ovaries. Follicle membranes from isolated oocytes were enzymatically digested with 2 
mg/mL collagenase (Type 1A, Sigma). Selected oocytes were injected with 20–50 nL 
of DEPC-treated water (diethyl pyrocarbonate, Sigma) containing the different cRNAs 
at a concentration of 500 pg/nL/subunit. Oocytes were stored at +18°C in modified 
ND96 solution (90 mM NaCl, 1 mM CaCl2, 1 mM KCl, 1 mM MgCl2·6H2O, and 5 mM 
HEPES, Sigma). Recordings were performed at days 3-4 after oocyte injection. 
Currents through AtGLR1.4C∆610W and GluA2(Q)flop(L483) receptors were 
measured at room temperature (20-24°C) by means of the two-microelectrode voltage 
clamp technique making use of a TURBO TEC-05X amplifier (NPI Electronic). 
Currents were elicited at a holding potential of -100 mV. Data acquisition was carried 
out by means of an Axon Digidata 1440A interface using pCLAMP v.11 (Molecular 
Devices). ND96 (96 mM NaCl, 1.8 mM CaCl2, 2 mM KCl, 1 mM MgCl2·6H2O, and 5 
mM HEPES, Sigma) was used as bath solution. Microelectrodes were filled with 3 M 
KCl and had resistances between 1 and 3 MΩ. 
 
2.2.6.2 Fast Perfusion System 
Compounds were applied by means of a solution exchange system as described 
previously [81]; drug or control solutions were applied by means of a TECAN Miniprep 
60 enabling automation of the experiments (ScreeningTool, NPI Electronic). To elicit 
currents, the chamber (holding volume 15 μL) was perfused with 250 μL of compound-
containing solutions at a volume rate of 200 μL/s [82]. For experiments determining 
kinetic properties of the channel, solutions were applied at a volume rate of 400 µL/s. 
To account for possible slow recovery from increasing levels of desensitization in the 
presence of high compound concentrations, the duration of washout periods was 
extended stepwise, i.e. 1 min (≤3 µM compound) to 1.5 min (≤10 µM) to 2.5 min (≤100 
µM) to 5 min (≤1 mM) to 15 min (≤10 mM). Oocytes with maximal current amplitudes 
>5 µA were discarded to exclude voltage-clamp errors. Concentration-response 
curves were generated, and the data were fitted by non-linear regression analysis 
using ORIGIN 7.0 (OriginLab Corporation). Data were fitted to the Hill equation: y = 
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min + (max – min) * xn/(knH + xnH) with k corresponds to the EC50 value, x-values are 
logs of concentration, and nH is the Hill coefficient. Each data point represents the 
mean ± SEM from at least 2 oocyte batches. Data was analyzed in Clampfit 10.1. 
(Molecular Devices) 
 
 
 
2.2.6.3. HEK 293 cells  
Whole-cell patch-clamp recordings were performed as described [76] with 
modifications as follows. Pipettes (Bo-glass capillaries fire polished OD 2.0 ID 1.5 
Hilgenberg) were pulled to resistances of 4-6 MΩ (Sutter Instruments) and were filled 
with an internal solution (135 mM K-gluconate, 6 mM NaCl, 4 mM MgCl2, 2 mM 
NaATP, 1 mM EGTA, 10 mM HEPES, pH 7.4). A home-made gravity perfusion system 
containing extracellular solution (ECS) (145 mM NaCl, 4 mM KCl, 1 mM MgCl2, 2 mM 
CaCl2, 10 mM HEPES, 10 mM sucrose, pH 7.4 adjusted with NaOH) alone or with 0.1 
or 1 mM L- methionine or 1 mM L-arginine, was continuous at an average flow rate of 
around 40 - 80 μL/s. For amino acid profiling, ECS was exchanged for extra synaptic 
solution (ESS) ((0.14 mM L-arginine, 0.45 mM L-lysine, 0.025 mM L- valine, 0.005 mM 
L-cysteine, 0.05 mM L-threonine, 0.045 mM L-alanine, 0.05 L-histadine, 0.07 L-serine, 
0.025 mM L-lysine, 0.015 mM L-isoleucine, 0.650 mM L-glutamine, 0.01 mM L-
methionine in ECS, pH 7.4 all amino acids were added from fresh (<2 weeks at 4°C) 
100-250 mM stock solutions made in house in H20, Sigma)) and then exchanged for 
ESS containing 0.1 or 1 mM Met. Cells expressing AtGLR1.4_eYFP, iMetR or variants 
were identified using a polychrome V monochromator (Tillphotonics). Wavelength of 
497 nm (bandwidth (BW) 16 nm, Thorlabs) was directed to either a 20, 40, or 63x 
objective (Olympus) using a Dichroic filter (R Band = 490–510 nm, T Band = 520–700 
nm, Thorlabs) and an emission filter for 535 nm (BW 22 nm, Thorlabs) through an 
illumination port in the microscope (IX 50, Olympus). Data was acquired in voltage 
clamp mode with an Axopatch 200B amplifier (Axon instruments) controlled by pClamp 
10 software with Digidata 1440A interface (Molecular Devices) 48-72 h after 
transfection and was recorded with pClamp 10 software (Molecular Devices), which 
was also used to regulate the polychrome. Data was filtered at 2 kHz. For current-
voltage (I/V) relationships, current was first acquired in gap free mode at -70 and 0 mV 
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hold. Data was obtained using a ramp step protocol from -80 – +80 mV over 5 sweeps 
with a delay of 1 s between sweeps. Met I/V curves were plotted with a baseline ramp 
subtraction off line. All current analysis was performed offline in Clampfit 10.1 and 
further analyzed in Igor 6.34A (WaveMetrics).  
 
 
2.2.6.4 Hippocampal Slice Preparation 
Acute transverse hippocampal slices (400 μm thick) were prepared from mice 8–
14 days post-injection (dpi). Briefly, the hippocampi were isolated and cut in a 
VT1000S or VT1200S vibrotome (Leica) in an extracellular solution containing 215 
mM sucrose, 2.5 mM KCl, 20 mM glucose, 26 mM NaHCO3, 1.6 mM NaH2PO4, 1 mM 
CaCl2, 4 mM MgCl2, and 4 mM MgSO4. Thirty minutes after sectioning, the cutting 
medium was gradually switched to an artificial cerebrospinal (ACSF) recording 
solution containing 124 mM NaCl, 2.5 mM KCl, 26 mM NaHCO3, 1 mM NaH2PO4, 2.5 
mM CaCl2, 1.3 mM MgSO4, and 10 mM glucose. All solutions were equilibrated with 
95% O2 and 5% CO2 (pH 7.4). Slices were incubated for at least 60 min in ASCF 
solution before recordings. Hippocampal slices were visualized using 
infrared differential interference contrast (IR/DIC) and GFP fluorescence. All slices 
included in this study exhibited strong fluorescence in dentate gyrus. Experiments 
were performed at 26.0°C ± 1.0°C in a submersion-type recording chamber perfused 
at ∼1.5 ml/min with ASCF. Data was acquired in current clamp mode with an Axopatch 
200B amplifier (Axon instruments) controlled by stimfit software with Digidata 1440A 
interface (Molecular Devices) All recordings were acquired in whole-cell patch clamp 
configuration.  After baseline establishment a glass pipette (1MΩ) filled with 10 mM 
Met in ACSF was directed to the recording neuron and brief puffs were applied.  After 
application of Met returned to baseline was monitored.  
 
2.2.7. Antibody labeling  
At DIV15-18 transduced hippocampal neurons were checked for morphological health 
and channel expression using a fluorescent lamp (EVOS YFP) and were subsequently 
labeled for immunofluorescence. For staining, neurons were fixed with 4% PFA in 50% 
(v/v) culture medium for 10 minutes at RT. Cells were washed 3x with PBST (0.1% v/v 
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Tween, Sigma in PBS) and incubated in permeabilization buffer (0.25% v/v Triton 100x 
Sigma in PBS) for 20 min at RT. Cells were washed 3x with PBST and incubated with 
blocking solution (1% BSA Sigma w/v in PBST) for a minimum of 1 h at 37°C. Labeling 
was carried out in a wet chamber with primary antibodies against GFP (rabbit anti-
GFP dilution 1:750, ab290, AbCam), glutamate ionotropic receptor NMDA type subunit 
1 (GluN1) (mouse anti-GluN1 dilution 1:100, #114011, Synaptic Systems), glutamate 
ionotropic receptor AMPA type subunit 2 (GluA2) (rabbit anti-GluA2 dilution 1:500)  post-
synaptic density protein 95 (PSD-95) (mouse anti-PSD-95 dilution 1:200, #MA1-046, 
Thermo Fisher Scientific), and microtubule associated protein 2 (MAP2) (guinea pig 
anti-MAP2 dilution 1:1000, #188004, Synaptic systems) overnight (16 h) at 4°C. Glass 
coverslips were transferred to a 24-well plate and washed 4x with PBST and 
transferred back to the wet chamber for incubation with corresponding secondary 
antibodies (goat-anti-mouse STAR RED, dilution 1:1000, # 2-0002-011-2, Abberior®, 
goat-anti-rabbit STAR 580 # 2-0012-005-8 , dilution 1:500, Abberior®, goat-anti-guinea 
pig Alexa Fluor® 488 #A11073, dilution 1:500) for 1 h in the dark at RT. Coverslips 
were washed 3x with PBS in 24-well plates, washed once with ultrapure water, 
mounted on micro slides (Assistant) with Mowiol mounting medium and left to dry at 
RT. For STED imaging samples were imaged within 6 h of mounting.  
 
2.2.8. Imaging 
2.2.8.1 TIRF/Confocal microscopy 
A Zeiss Axio Examiner Z1 inverted microscope equipped with Plan-Apochromat 
objectives (10x NA0.45 Air, 20x NA Air and 63x, NA 1.4 oil) was used to image brain 
slices. Images were obtained with an Ar laser with 514 nm and a PMT detector. A 
Zeiss inverted LSM 700 confocal microscope equipped with a Plan-Apochromat 
objective (40x. NA 1.2 Water) was used to image transfected HEK cells expressing 
GluA2(flop)_eGFP, iMetR and iMetR channel variants with a laser line at 488 nm and 
acquired with a PMT detector. TIRF images were acquired with an Olympus IX83 
microscope equipped with cell^TIRF module. An Olympus UApo oil immersion 
objective (100x, NA 1.49) was employed to image HEK 293 cells expressing iMetR 
and GluA2(flop)_eGFP (GluA2_eGFP) in TIRF illumination. An excitation wavelength 
of 488 nm for mVenus and eGFP was used to obtain images with a quad line beam 
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splitter emission filter (Chroma) and an EM-CCD camera (Hamamatsu). To assess 
stable membrane expression live samples were imaged for 120 frames at 1 Hz. All 
Images were assessed in Image J. 
 
2.2.8.2 STED imaging  
Super Resolution images of PSD-95 and GluN1 labeled neurons expressing iMetR 
and variants were acquired on a commercial STED Microscope (Abberior Instruments) 
using the Imspector software (Abberior) and equipped with a UPLSAPO 100X Oil 
objective (Olympus) . iMetR, transduced cells were first identified using a red LED (585 
nm) through the eyepiece. Subsequently, co-staining for MAP2 (488 nm) and PSD95 
positive spines (640 nm) in confocal microscopy was used to identify dendrites. Two 
color STED images of PSD-95 and mVenus, GluN1 and mVenus, were acquired using 
7.24 μW/561 laser, 15.22 μW/640 laser and 123.4 mW/775 laser (STED) with 6 line 
steps for each channel. The corresponding confocal images were acquired 
simultaneously using 7.24 μW/561 laser and 15.22 μW/640 laser with 1 line step for 
each channel. For both STED and confocal images pixel size was set to 20 nm and 
dwell time per pixel was 15 μs. Gating time for STED imaging was adjusted to exclude 
detection of the confocal halo generated by early spontaneous emission. Image 
analysis 1 and 2 were both performed in Image J Analysis 1 employed the TrackMate 
plugin to analyze particles. 
 
 
2.4. Results 
2.3.1. Electrophysiological characterization of iMetR in heterologous expression 
systems 
The goal of our study was to develop a receptor with GLR-topology into an orthogonal 
synthetic neurobiology tool that takes advantage of GLR evolutionary adaptations (Fig 
2.1A). In order to determine whether AtGLR1.4 was functionally expressed in 
mammalian cells without modifications, we transfected HEK 293 cells with a vector 
encoding for a YFP-tagged version of the protein. We initially examined if we could 
induce observable current upon bath application of Met in whole cell patch clamp 
experiments. AtGLR1.4 in oocytes is strongly inwardly rectifying at negative potentials 
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[63]. Application of 0.1 or 1 mM Met did not result in detectable current, even at very 
negative potentials (-100mV).  
AtGLR1.4 shares structural aspects (see above) with iGluRs, specifically the 
Ca+2 permeable NMDA receptors (NMDAR), which have the highest sequence identity 
with the ligand binding domain (LBD) of AtGLR1.4 [83]. However, key signaling motifs 
for the mammalian secretory pathway, which reside in the N and C terminal regions of 
iGluRs [84-88] are not present in AtGLR1.4 [63, 72]. Previous work on microbial 
proteins has shown that applying molecular principles to receptors of interested can 
optimize transcellular trafficking in mammalian cells. This has also been applied to 
engineered iGluRs [49]. We reasoned that the channel might be retained in one or 
more subcellular secretory organelles and therefore have low or unstable membrane 
expression. To address this we optimized AtGLR1.4 by incorporating motifs that 
encode trafficking signals for excitable cells (Fig 2.1B, C). We replaced the AtGLR1.4 
signal peptide with a neuronal nicotinic acetylcholine receptor β subunit (nβAchR) 
signal peptide and attached a membrane trafficking signal from the inwardly rectifying 
voltage-gated potassium channel 1.2 (Kir1.2) directly before the stop codon in 
AtGLR1.4, followed by a mVenus visualization tag. Furthermore, an endoplasmic 
reticulum (ER) export signal, also from Kir1.2, was placed directly after mVenus with 
a stop codon (Fig 2.1C). The chimeric channel gene was then further codon optimized 
for mammalian expression and named iMetR1.0. iMetR1.0 could be easily identified 
on the membrane of HEK 293 cells both in TIRF microscopy and in confocal 
microscopy (Fig 2.1D). Time lapse images taken of HEK cells expressing iMetR1.0 in 
TIRF show stable membrane expression that can be observed with lateral movement 
in the membrane [89]. In comparing confocal images of GluA2_eGFP with iMetR1.0 
we found that iMetR1.0 exhibited enhanced clearing of the ER over that of 
GluA2_eGFP (Fig 2.1D). However, whole cell recordings of iMetR1.0 were absent of 
any detectable current in HEK 293 cells upon application of 1 mM Met (data not 
shown). Furthermore, while Met induced currents were not present we could detect 
current from cells expressing GluA2_eGFP, suggesting that membrane expression 
was not the primary reason for the lack of iMetR current.  
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Fig 2.1. Orthogonality and optimization of a plant GLR for mammalian cell 
membrane expression (A) Concept of evolutionary orthogonality using a plant 
GLR. (B,C) Cartoon of modified AtGLR1.4 with exchanged and tagged motifs, and 
pore point mutation (red) (D) iMetR shows enhanced membrane expression in HEK 
293 cells compared to GluA2_eGRP (TIRF, 100x), first and third panel; (confocal, 
40x), second and fourth panel. All scale bars denote 5 μm. 
 
 
Previous work in oocytes found current amplitude below 0.1 µA for AtGLR1.4 [63], and 
this result combined with robust protein expression is indicative of a small single 
channel conductance and offers a potential explanation for the lack of observable 
current in HEK 293 cells. We sought to increase channel conductance by introducing 
a point mutation identified by the Hollmann lab at position 610 from cysteine to 
tryptophan (AtGLR1.4∆C610W; Fig 2.1C) that reported a significant increase in 
current amplitude in oocyte electrophysiological recordings (D. Tapken, unpublished 
results). Indeed, in oocyte recordings with AtGLR1.4∆C610W gave current amplitudes 
around 3.5-fold average current amplitudes at 0.1 (0.32 ± 0.07 mean ± SEM., n = 10) 
or 1 mM Met (0.35 ± 0.09 mean ± SEM., n = 9) over the reported, with maximum 
current detected around 1 μA. This mutant was then also employed in mammalian 
cells.  Taking advantage of detectable currents in oocytes and using an automated 
fast perfusion system [81], we tested whether AtGLR1.4∆C610W carries the 
desensitizing characteristics of iGluRs. At an exchange time of around 40 ms (400 
25 
 
µL/s, chamber volume 15 µL) we observed very weak desensitization compared to an 
engineered GluA2 [90, 91] (τon 460 ± 54 ms, mean ± SEM., n= 8) (Fig 2.2A).  
AtGLR1.4 gating responses to signaling molecules that are present in plants 
were tested in previous reports [63]. The tested signaling molecules included well 
known mammalian neurotransmitters (NT), such as glutamate (Glu), glycine, 
aspartate, dopamine (Dopa) and acetylcholine (Ach). To further deduce if iMetR1.0 
would exhibit potency to endogenous mammalian NTs, we also examined whether ɣ-
aminobutyric acid (GABA), the major inhibitory NT in the mammalian CNS, induced 
channel opening We found that the channel was not gated by GABA (Fig 2.2B) and 
we further confirmed that neither Glu, Ach nor Dopa were effective agonists of 
AtGLR1.4∆C610W (Fig 2.2B).  
 
 
 
Fig 2.2. Analysis of AtGLR1.4 gating. (A) AtGLR1.4∆C610W gating response to 
fast application of Met (0.1 mM) versus gating response of GluA2(Q)flop(L483F) to 
Glu (0.1 mM) (B) Representative current traces elicited from AtGLR1.4∆C610W in 
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response to application of major NTs (0.1 mM for each compound, left), average 
current amplitudes of NTs normalized to current response from 0.1 mM Met (right 
bar graph) (C) Cartoon of agonist and antagonists on channel gating (D) Met dose 
response curve for AtGLR1.4∆C610W in response to application of 0 (circles),10 
(squares), 30 (triangles), and 100 µM (diamonds) Arg. All scale bars represent 0.1 
µA and 10 s. Data shown as the mean, error bars denote ± SEM., n = 8 for each 
condition.  
 
 
2.3.2. Natural amino acids act as “on/off” switches of iMetR gated currents 
In line with its role as an amino acid sensor in plants, a broad spectrum of other 
natural amino acids act as agonists or even antagonists of AtGLR1.4 [63]. We sought 
to take advantage of this promiscuous ligand binding profile by identifying a molecule 
that could endow a natural “off” switch to the channel, in experiments that mimic the 
pharmacological profile of Met in neuronal tissue. Of the natural amino acids that 
showed antagonistic behaviour, Arg exhibited the highest potency [63]. Arg is an 
essential amino acid in the mammalian brain and precursor of nitric oxide [92] yet like 
Met, Arg is not a molecular component of electrical transmission in the mammalian 
brain. In order to assess the competitive interaction of Met and Arg on 
AtGLR1.4∆C610W we performed Arg dose-response measurements in the presence 
of Met (Fig 2.2D). Consistent with previous findings for AtGLR1.4, application of 
increasing concentrations of Arg (0.01 – 0.1 mM; EC50 7.15 ± 0.45, 16.6 ± 4.14, 40.92 
± 11.56, and 131.94 ± 21.81 µM; Hill coefficients 0.9 ± 0.04; 0.7 ± 0.09, 0.52 ± 0.056, 
0.6 ± 0.04, respectively, data shown as the mean ± SEM) shifted the Met dose-
response curve (Fig 2.2D) demonstrating that Arg is a potent competitive antagonist 
of Met-induced currents in AtGLR1.4∆C610W at a wide concentration range. 
 We went on to validate this result in mammalian cells. We applied the high 
conductance substitution to the pore domain of iMetR1.0 (position 599 corresponds to 
the altered position in AtGLR1.4∆C610W (Fig 2.1C)). We also tested additional 
substitutions at position 599, including substitutions to serine (Ser), alanine (Ala), 
histidine (His) or tyrosine (Tyr). These substitutions did not result in detectable current 
(in the case of Ser, Ala and His) or smaller currents (in case of Tyr; data not shown). 
A codon optimized version of iMetR1.0C∆599W was subsequently referred to as 
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iMetR. iMetR had the same expression pattern in HEK 293 cells as iMetR1.0 and gave 
detectable current upon 100 µM Met (Fig 2.3A). Next we examined whether Arg would 
act as a sufficient “off” switch. Upon application of 1 mM Arg we saw an elimination of 
channel current that could be rescued with an exchange of bath solution containing 
Met (Fig 2.3A). The current-voltage relationship of iMetR showed sharp inward 
rectification at negative potentials in whole cell voltage clamp mode (Fig 2.3B) with a 
reversal potential of 11.7 ± 6.1 mV.  
 
 
2.3.3. iMetR exhibits graded dose response in a simulated in vivo environment  
As mentioned above, AtGLR1.4 has been shown to bind a range of amino acids that 
are found in their free form in the mammalian brains’ interstitial fluid (ISF). Next, we 
tested whether these amino acids would inhibit gating by Met in vivo. We performed 
an in depth search of mammalian microdialysis literature to determine the probable 
concentrations of those amino acids that showed significant potency for AtGLR1.4 in 
the ISF. We compared these concentrations against the reported EC50 and percent 
inhibition for AtGLR1.4, to determine which amino acids were necessary to test in 
conjunction with Met gating (Table 2.1). The composition of this custom bath solution, 
which we referred to as extra-synaptic solution (ESS) comprised mostly of antagonistic 
amino acids (R, K, V, C, A, H, S, I, Q) and a few agonistic amino acids (M, T, L) (see 
methods and Table 2.1 for concentrations). We found that application of ESS exhibited 
the same inhibitory block of the iMetR current as Arg alone when exchanged for normal 
bath solution (ECS) (Fig 2.3B). When we exchanged ESS with ESS containing a low 
concentration of Met (0.1 mM) only about 25% (27.5 ± 6.1 data shown as the mean ± 
SD) of the current could be recovered, yet when we exchanged bath solution for ESS 
containing a high level of Met (1 mM) around 90% (88.9 ± 10.8 data shown as the 
mean ± SD) of the Met induced current detected in ECS could be recovered (Fig 2.3 
C,D). This finding shows that there is a natural intrinsic block in the mammalian brain 
that will inhibit any spontaneous channel opening as well as show that a graded acute 
increase in exogenously applied Met will activate iMetR, in a concentration dependent 
manner.  
The apparent lagged kinetics of iMetRs versus iGluRs in terms of chemogenetic 
or SNT application will most likely not be a hinderance as Met will not be cleared as 
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fast as a native neurotransmitter therefore allowing a sustained depolarized state  
which may coincide with synaptic release events and facilitate modulation of synaptic 
or neuronal behaviour.
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Table 2.1 [Amino acid] profile in simulated ISF  
Agonist 
Amino Acid 
Brain region Flow rate (µl/min) [Microdialysate] (µM) % of IMet EC50 (µM) [ESS] (µM) Source 
Met Hippocampus 2* 6.4 100 7.30 ± 0.55 10  [93]* 
Trp Cortex 1 3.84 42.5 ± 3.1 49.5 ± 3.1 0  [94] [95] 
[96] [97]  
[98]   
Phe Hippocampus 2* 8.8 24.4 ± 0.7 103 ± 4 0  [93] [95] 
Leu Hippocampus 2* 22 24.0 ± 1.0 31.5 ± 1.8 25  [93] [99] 
Tyr Hippocampus 2* 10.4 18.6 ± 1.6 188.9 ± 19 0  [93] [98]  
Asn Hippocampus 2* 6.8 18.1 ± 0.5 264 ± 7 0  [93] [100]  
[95] [101] 
Thr Hippocampus 2* 46 13.8 ± 1.2 52.6 ± 1.4 50  [93] [100] 
Norleucine n/a n/a n/a 16.5 ± 0.8 26.4 ± 3.5 (excluded****) n/a 
*PD 
2051
165 
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Antagonist 
Amino Acid 
Brain region Flow rate (µl/min) [Micro dialysate] (µM) % of 0.1 mM IMet % of 1 mM IMet [ESS] (µM) Source 
Arg Hypothalamus 1.5** 122** 80 48 150  [94] [95] [102]  
Gln Hippocampus 2* 651* 78 32 650  [93, 94] [100] [95] 
[101] [103] [104] [105] 
[99] 
Lys Hypothalamus 1.5**  450.4** 68 23 450  [95] [102] 
Val Hippocampus 2* 22.8 55 18 25  [93] [101] 
IIe Hippocampus 2* 10.4 50 15 15  [93] 
His No data found No data found No data found 50 12 50***  [106] 
Cys Cortex 2* 3.84 48 10 5  [107] [98]  
Ala Hippocampus 2* 42 40 8 45  [94] [93] [100] [95] 
[101] [103] [102] [99] 
Ser Hippocampus 2* 69.9 15 3 70  [93] [100] [95] [103] 
Microdialysate concentrations are shown as the mean plus one standard deviation. Concentrations included in ESS represent  a rounded number from microdialysate for convenience purposes. 
All amino acid concentrations with the exception of histidine were acquired from literature using in vivo microdialysis (source  in bold).  In the case where there was a range of concentrations for 
an amino acid, the upper limit concentration was applied. 
*[aa] in dialysate was multiplied by a factor of 40 on the basis that the recovery rate for amino acids in vitro was 5% for the dialytrodes used in the study. Data was adjusted on the recommendation 
of the authors to account for a 50% recovery rate of in vivo for chronic implants in anesthetized animal [93] Correction PMID reference 2051165 . 
** awake behaving animals, in vitro recovery rate 5-10%, lower recovery limit was taken [102] 
*** no microdialysis data available - included due to precursor to histamine  
**** no microdialysis data available – excluded 
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Fig 2.3. Natural amino acids act as an “on/off” switch in HEK 293 cells 
expressing iMetR and graded responses in a simulated in vivo environment 
(A) Activation of iMetR with Met (0.1 mM) which is reversed with Met wash out or 
blocked by Arg (1 mM) wash in (B) Met induced current-voltage relationship  (ramp 
from -80 - + 80 mV), currents were normalized to the maximum amplitude at -80 mV 
(n=3). (C) Cartoon of amino acid profile on iMetR with bath exchange of ESS 
(above), iMetR representative whole cell current traces in HEK 293 cells in 
application to ESS, ESS with low Met (0.1 mM), or high Met (1 mM) (D) iMetR current 
is reduced in ESS with low Met and recovers in ESS with high Met (1 mM), shown 
as percent of Met current responses in normal bath solution (0.1 M Met) (n is 
represented above each condition). Cells were held at -70 mV in whole cell voltage 
clamp mode. Data shown as the mean, error bars denote ± SD., all scale bars 
represent 0.05 nA and 50 s 
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2.3.4. iMetR variants with C-terminal post-synaptic targeting motifs  
After demonstrating the suitability of iMetR for manipulation of neuronal electrical 
signals with respect to ligand binding and ion conduction properties, we further 
modified the protein for functional enhancement in neurons. We reasoned that 
transferring signaling motifs from proteins that localize post-synaptically would 
increase site directed expression of iMetR and, due to the slow kinetics of the channel, 
an increase in retention at post-synaptic sites may enhance the modulation of post-
synaptic potential. We therefore engineered two C-terminal motif variants, one that 
replaced the C-terminus (CT) of iMetR with that of GluA2 (iMetR∆R2ct) and one that 
incorporated the last 15 amino acids from stargazin (ɣ2) directly after the CT which 
contains the PDZ binding domain (iMetRɣ215) (Fig 2.4A). Confocal images for both 
variants expressed in HEK 293 cells show expression patterns similar to that of iMetR 
(Fig 2.4B). Surprisingly, iMetRɣ215 showed 3-fold increase in current whereas 
iMetR∆R2ct currents were comparable to iMetR (Fig 2.4C, D). We reasoned that this 
may be due to an increased channel conductance or an increase in membrane 
expression of iMetRɣ215. Because both of these properties are known to be modulated 
by ɣ2 [108-110] we tested whether co-expressing ɣ2 and iMetR or iMetR∆R2ct would 
result in the same effect on current amplitude.  
 
 
 
 
Fig 2.4. Tagging iMetR with a post-synaptic density retention signal conveys 
increased channel conductance (A) Cartoon of iMetR CT modifications (B) 
Confocal images of iMetR co-expressed with ɣ2 (left panel), iMetRɣ215 (middle 
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panel), and iMetR∆R2ct (right panel) (C) representative currents from HEK 293 cells 
expressing iMetR, iMetRɣ215, and iMetR∆R2ct co-transfected with empty vector 
(left) or ɣ2. Cells were held at -70 mV in whole cell voltage clamp mode. Scale bars 
represent 0.1 nA and 20 s. Data shown as the mean, error bars denote ± SEM., n is 
represented above each condition. 
 
 
It was a surprising that iMetR∆R2ct did not exhibit an increased current 
amplitude with ɣ2 co-expression (Fig 2.4D) as it is the variant that contains the most 
enhanced form of iGluR trafficking and complexing signals. One likely explanation is 
that this channel variant is already efficiently targeted to the membrane.  
 
 
2.3.5. iMetR∆R2ct co-localizes with NMDA receptors but shows no preference for 
post-synaptic densities 
Next, we investigated iMetR expression in neurons both in vitro and in vivo. Upon 
transduction of dissociated hippocampal cultures using lentivirus we found that all 
variants showed good membrane expression (Fig 2.5). We further sought to determine 
whether the additional tags normally associated with post-synaptic densities would 
increase localization of the channels in a synapse specific manner. We employed 
immunolabeling and 2-color stimulated emission depletion (STED) microscopy to 
assess whether iMetR channels localized with PSD-95 signals and therefore are likely 
present in post-synaptic densities. We also tested for localization with GluN1, the 
necessary subunit in N-methyl-D-aspartate receptors, to determine whether there was 
spatial overlap with endogenous iGluRs independent of PSD. For image analysis 1 
(Fig. 2.5 D) of overlapping iMetR puncta with PSD-95, the lower limit area restriction 
for PSD-95 was set at 10 nm2 [111, 112] and no upper limit restriction. We used these 
parameters to distinguish synaptic regions. We did not discriminate in location of 
NMDAR densities due to the difficulty in discriminating between localized channels, 
those in transit, and those waiting for recruitment [113]. We found that there was 
overlap in all channels with PSD-95 yet no discernable difference between iMetR, 
iMetR∆R2ict, or iMetRɣ215 (Fig 2.5 D-F). Inclusion of GluA2 densities and restriction 
of PSD-95 puncta set at a between 10 - 540 nm2 using analysis 2 (Fig 2.5 L) We found 
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that there was overlap in all channels with PSD-95 but a significant difference between 
GluA2, iMetR∆R2ict, or iMetRɣ215 and iMetR (Fig 2.5 G-K).  This indicates the 
importance of  
 
 
 
 
Fig 2.5. 2-color STED reveals iMetR localization to post-synaptic densities in 
hippocampal neurons (A) Representative confocal images of dendritic (MAP2) and 
post-synaptic density (PSD-95) markers in a hippocampal neuron expressing 
iMetR∆R2ct, overlay image boxed where STED was applied. (B) STED resolved 
image of PSD-95 (magenta) and iMetR∆R2ct (green), boxed image in overlay is a 
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representative section that was enlarged for analysis (C, D). Images were analyzed 
separately, endogenous staining was blurred using a Gaussian filter, sectioned into 
binary spots and subtracted from iMetR channels (green) using TrackMate, particles 
within defined regions were counted as localized to PSD-95. (E) Representative 
pictures of iMetR channel variants overlaid with PSD-95. All identified PSD-95 
regions and iMetR puncta were averaged over the number of PSD-95 regions with 
the same image (D, E, F). GluA2 puncta (G) and removal of the background to show 
GluA2 puncta for localization (H), PSD-95 puncta (I) and puncta after background 
removal and size restriction (J).  GluA2 and PSD-95 overlay (L) show those regions 
in white are identified as GluA2 particles found within PSD-95 puncta (K). For 
Analysis 1, n = 135, n = 1570, and n = 757, for iMetR, iMetR∆R2ct, and iMetRɣ215 
respectively, n represents PSD-95 puncta over 2-8 images. For analysis 2, n = 478, 
n = 25, n = 642, n = 1648 for GluA2, iMetR, iMetR∆R2ct, and iMetRɣ215 respectively, 
n represents overlay particles over 2-13 images. Data shown as the mean, error 
bars denote ± SD. * = p <0.05, two-tailed t-test with Welch’s correction. 
 
We did observe a significant difference in the localization of iMetR∆R2ct with 
GluN1 over that of unmodified iMetR using analysis 1 from above (Fig 2.6) with no 
restrictive limits for the reasons stated above on channel particles. Due to the nature 
of introducing exogenous proteins as well as the phenomena of synaptic scaling [114, 
115] iMetR∆R2ct may compete with native GluA2’s for slots in the PSD, which could 
be an explanation for why we found no preference for iMetR∆R2ct over iMetR in PSD-
95 localized areas 
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Fig 2.6. iMetR∆R2ct exhibits preferential targeting to iGluR “slots” 
Representative images in Confocal (top panels) and STED (bottom panels) 
resolution of hippocampal dissociated culture labeled against GluN1 subunit 
(magenta) and mVenus (green), dendritic structures expressing (A) iMetR∆R2ct or 
(B) iMetR. (C) iMetR∆R2ct shows a significant increase in localization with GluN1 
over iMetR. Data shown as the mean, error bars denote ± SD., n = 1156 and n = 
532 for iMetR and iMetR∆R2ct, respectively, n represents NMDAR puncta over 7-9 
images * = p < 0.05, two-tailed student’s t test.  
 
 
 
In addition, all variants of iMetR showed high expression when virally expressed 
in the dorsal dentate gyrus (DG) of mice. iMetR expression was compared to either 
iMetR∆R2ct or iMetRɣ215 by unilateral expression into the left hemisphere for iMetR 
and one variant into the right hemisphere of the same animal. Expression was 
assessed after 15 d with confocal microscopy (Fig 2.7).   
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Fig 2.7 iMetRs express in vivo in the dorsal DG of mice (A) iMetR (10x) scale 
bar represents 100 µm, insert scale bar represent 10 µm (40x) (B) iMetRɣ215, and 
(C) iMetR∆R2ct, (40x) scale bars represent 10 µm.  
 
We performed slice electrophysiology on dentate granule cells that exhibited 
expression of iMetRɣ215 due to the increased amount of current observed in HEK 293 
cell and preferential spine localization determined by 2-color STED.  Application of Met 
using a guided pipette onto the cell body induced specific depolarization steps 
depending on the length of application (Fig 2.8 A) but did not induce action potentials.  
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However, application of Met to the dendritic arbor did induce action potential firing 
suggesting that iMetRɣ215 expression in neurons with a combination of increased 
channel current and subcellular retention is sufficient to initiate action potentials. 
Further electrophysiological experiments are required to determine whether and to 
what extent somatic versus dendritic Met application effects the depolarizing state of 
neurons expressing iMetRɣ215. 
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Fig 2.8 Subcellular Met application of iMetRɣ215 induced action potentials in 
Hippocampal neurons (A) Somatic Met puff induced membrane depolarization which 
was not observed with ACSF puff on iMetRɣ215 expressing neurons or untransduced 
neurons in the same layer with Met application (B) Dendritic Met puff induced action 
potentials on neurons expressing iMetRɣ215. Each trace represents an n = 1. 
 
 
2.5. Discussion 
The past two decades have seen a paradigm shift in neuroscience research with the 
advent of genetically encoded tools that allow researchers to manipulate neuronal 
communication in a cell type-specific manner. Existing chemogenetic techniques 
exclusively rely on ligands that are non-natural but designed to activate engineered 
receptors. Non-natural designer ligands pose specific concerns in terms of ligand 
clearing (no endogenous system in place) and orthogonality (reactivity with un-
targeted receptors) that could lead to possible off target effects including unrealized 
circuit or system-wide gain of function. We have, in part, addressed these limitations 
by identifying a natural ligand – receptor pair where the ligand retains its natural 
properties and in which the system has native housekeeping abilities for, while acting 
orthogonally in a mammalian system and specific activation of its receptor.  
Ion channels are ideal receptors to employ in a chemogenetic strategy because 
they directly control ion fluxes, which can be further tuned by means of engineered 
pore properties. We re-purposed a plant GLR to induce bioelectric signals in 
mammalian cells with the ultimate goal of modulating excitable cells, by its natural 
ligand. The three clades of GLRs expressed in A. thaliana share similarities both in 
structural topology and functionality with mammalian iGluRs. Specifically, AtGLR1.4 is 
a mixed cation channel from the clade 1 family, notably permeable to calcium that has 
been well characterized in the heterologous system oocytes from X. laevis. 
iMetR is an attractive candidate chemogenetic tool because of the properties 
of its primary ligand Met (e.g. low toxicity, inexpensive, BBB permeability, and a 
common PET tracer). As with any biochemical tool, there are considerations to the 
use of natural aminos as “designer” ligands. Both Met and Arg are known to be 
neuroprotective amino acids [116-119] and off target affects may confer 
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neuroprotective qualities that could be beneficial in counteracting damage done during 
experimental procedures (e.g. viral injections).  
We optimized this channel for mammalian cells, using combinatorial molecular 
modification to assist channel trafficking through secretory pathway for plasma 
membrane insertion. Inspired by previous work, we attached motifs for ER export and 
inserted a mammalian signal peptide. The engineered receptor iMetR exhibited 
enhanced ER clearing compared to the that of AtGLR1.4 (not shown) and GluA2, 
which allowed us to conclude that exchanging or adding small peptides, also in this 
case, assists non-mammalian proteins through a mammalian secretory path to 
membrane insertion. Additional enhancement can be applied, like those for trafficking 
out of the Golgi by seamless fusion of a Golgi export signal directly after the signal 
peptide [73]. However, expression of iMetR and iMetR variants both in vitro and in vivo 
lead to satisfactory membrane expression in the absence of this signal as shown by 
detectable currents upon Met application during whole cell patch clamp recordings in 
HEK 293 cells (in vitro) and microscopy (STED in vitro and confocal in vivo). 
Uniquely, this channel shows competitive antagonistic binding by amino acids 
other than its dominant agonist Met. Consequently, an “on/off” switch in the form of 
Met (on) and Arg (off) can be realized as a means to induce sharp or graded responses 
of bioelectric components in mammalian cells. Upon realizing this antagonistic 
behavior, we hypothesized that this may lead to an intrinsic block in vivo due to the 
range of amino acids that act antagonistically and are found as “free” in the ISF. We 
found that applying an artificial ISF named ESS, containing those amino acids that 
have significant potency profiles for AtGLR1.4 could sufficiently override Met gating. 
Yet, increasing the levels of Met in the ESS could efficiently rescue the Met-induced 
current at different levels compared to Met in a conventional bath solution or during 
system ‘loading’.  
In line with the concept of SNT, we created a number of iMetR variants with the 
goal to retain or accumulate the receptor in critical post-synaptic locations. Following 
literature on transmembrane AMPAR regulatory proteins (TARPs), we choose to first 
swap the entire CT of iMetR for that of GluA2. This decision was based on the following 
criteria. 1. The alignment of iMetR with that of all GluRs that are retained in the post-
synaptic density had no conserved residues [72], which implied that while expression 
may be universal, competition for space within the PSD would be low. 2. We reasoned 
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that an exchange of the CT for GluA2, which is the most abundant of the AMPAR 
subunits [120], would mimic AMPAR trafficking and retention in the PSD of excitatory 
synapses, which is the primary target site for proof of concept tests. In addition, and 
in line with the above, tag of a singular PDZ binding domain would be an alternative 
strategy to retain iMetRs in excitatory synapses without the selective GluA properties 
accompanying a full CT exchange. ɣ2 is a TARP that plays an active role in retention 
of proteins at the PSD. More specifically, ɣ2 interacts with PDZ domains of the post-
synaptic scaffolding protein PSD-95 [121]. We therefore took those 15 amino acids 
involved in PSD-95 binding, and added them between the end of the CT of iMetR and 
the membrane trafficking signal. In line with this hypothesis we used high-resolution 
imaging to determine if swapping CT would indeed show greater localization of iMetR 
and if the same held true for ɣ215 meant to confer direct facilitation with PSD-95. 2-
color STED imaging revealed that while iMetRs did localize to the PSD there was no 
preference for one over the other. However, the CT exchanged version did show 
enhanced localization with NMDARs. The observation that all iMetRs exhibited similar 
localization within regions containing PSD-95 may be explained by ubiquitous 
expression patterns due to the nature of channel overexpression.  
It has been speculated that an elongation of a PSD-95 binding domain may 
encounter less competition from other transmembrane proteins known to bind to PSD-
95 [122]. Therefore a simply elongation of the CT of iMetR∆R2ct with the same ɣ2 
PZD domain could further enhance retention in desired slots in the PSD due to the 
greater availability of PSD-95 slots deeper into the cytoplasm at synapses. 
Surprisingly, we found that the addition of ɣ215 conferred directly modulation of the 
channel and resulted in an increase of channel conductance and may be transferrable 
to iMetR∆R2ct. Due to the range of mobility and interactions between GluA2, ɣ2 and 
PSD-95 more conclusive STED imaging with endogenous GluA2 and PSD-95 in 
comparison to iMetR variants will be telling in how representative these iMetR variants 
are in relation to PSD-95 are in terms of preferential localization. Unlike in the case of 
other orthogonal ion channel systems that also assemble into oligomers, GLRs are 
not mammalian proteins and it is thus unlikely that unwanted protein-protein 
interactions with endogenous ion channels of the same superfamily will occur. 
Nevertheless, GLRs have retained enough structural topology to enhance channel 
qualities. GLRs including AtGLR1.4 receptor LBDs have been shown to gate pores 
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and pore loops of members of iGluRs in chimeric proteins [123]. Taking further 
advantage of these functional similarities the possibility exists of constructing a K+ 
selective receptor through the incorporation of a K+-selective pore, such as that from 
GluR0 [55, 124].  
Typically chemogenetic tools that are excitable often run into applicative 
problems like excitotoxicity owing to the fact that the off stage is reliant on clearing of 
a non-natural ligand. This may be addressed for a natural ligand like Met as there are 
uptake processes already there to clear it from the active cleft. These processes 
include metabolic pathways [125] as well as transporters for neutral amino acids (see 
chapter 4). These findings, in conjunction with the permeability of iMetR to calcium 
could be a way to apply remote synaptic plasticity paradigms in behaving animals. 
Overall, the specialized features of iMetR (structural topology, Ca+2 permeable, natural 
amino acid profile, and no reactivity to native NTs), as well as the pharmacological 
profile of Met and Arg, is a promising tool for neuronal modulation to address a range 
of modulatory behaviors.  Initial characterization of the iMetRɣ215 variant showed 
promise in applying iMetRs for cellular or subcellular override of neuronal 
communication. Further electrophysiological experiments in acute slice preparation 
will be telling to what extent Met-iMetR, iMetR∆R2ct, and iMetRɣ215, will affect overall 
neuronal output and to what degree this ligand-receptor combination can be applied 
in vivo.    
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3.1. Abstract 
Synaptic vesicles (SVs) are an integral part of the neurotransmission machinery, and 
isolation of SVs from their host neuron is necessary to reveal their most fundamental 
biochemical and functional properties in in vitro assays. Isolated SVs from neurons 
that have been genetically engineered, e.g. to alter protein content or introduce 
genetically encoded reporters, are not readily available but would permit new insights 
into SV structure and function. Furthermore, it is unclear if cultured neurons can 
provide sufficient starting material for SV isolation procedures. Here, we demonstrate 
an efficient ex vivo procedure to obtain functional SVs from cultured rat cortical 
neurons after genetic engineering with lenti virus. We show that 10(8) plated cortical 
neurons allow isolation of suitable SV amounts for detailed functional and biochemical 
analysis. We found that SVs isolated from cultured neurons have comparable 
neurotransmitter uptake as SVs isolated from intact cortex. Using total internal 
reflection fluorescence (TIRF) microscopy, we visualized an exogenous SV-targeted 
marker protein and demonstrate the high efficiency of SV modification. Obtaining SVs 
from genetically engineered neurons currently generally requires the availability of 
transgenic animals, which is constrained by technical (e.g. cost and time) and 
biological (e.g. developmental defects and lethality) limitations. These results 
demonstrate the genetic modification and isolation of functional SVs using cultured 
neurons and viral transduction. The ability to obtain SVs from genetically engineered 
neurons will permit linking in situ studies to in vitro experiments in a variety of genetic 
contexts. 
 
 
3.2. Introduction 
Synaptic vesicles (SVs) are small (40 nm diameter) secretory organelles that are 
concentrated at the periphery of active zones in neurons and play an integral part in 
synaptic communication. SVs harbor proteins that are essential for the packaging of 
specific neurotransmitters (NT), for positioning of diverse SV populations within the 
synapse and for SV fusion, in many cases in collaboration with cytosolic and cell 
membrane-localized protein binding partners [126-128]. SVs have in the past decades 
become classical models for the study of secretory organelles, and the alteration or 
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breakdown of their function lead to severe physiological consequences, including 
motor, neurodegenerative and neurological disorders [129-132]. 
In line with their vital functions, a plethora of experimental techniques have 
been developed to study all aspects of SV biology. SVs isolated from rodent brain 
tissue are the most common preparation to investigate SV protein composition and 
the specificity and energetics of NT uptake [133-135]. SVs are routinely visualized in 
situ in neuronal cultures and brain slices to study trafficking, fusion and recycling using 
fluorescent chemical markers, genetically encoded fluorescent probes and false 
fluorescent neurotransmitters [136-139]. Employing these techniques in vivo allows 
cellular and circuit dynamics to be investigated [140-143]. Finally, advanced 
microscopy techniques, such as total internal reflection fluorescent (TIRF) microscopy, 
offer complementary avenues to study isolated SVs and have been applied to detect 
variability in composition and energetics with single vesicle resolution [133, 144]. In 
the future, correlating biochemical and bioenergetic properties, which are obtained 
from the study of isolated SVs, with dynamic and functional properties, which are 
obtained from in situ observations, will likely yield new and fundamental insights into 
SV biology and synaptic function in health and disease. 
One of the most powerful strategies of inquiry across experimental biology is 
genetic perturbation. Overexpression or elimination of proteins of interest or delivery 
of genetically encoded functional probes are invaluable tools to understand cellular 
processes including those involving SVs [145, 146]. It is noteworthy that the 
application of genetic perturbation in experiments with isolated SVs has been limited 
[144, 147-149]. One major reason for this gap is that obtaining SVs from genetically 
modified neurons currently requires the generation of transgenic animals [144, 148, 
149]. Generation and maintenance of transgenic animals is costly and hampered by 
the fact that manipulation of many proteins associated with SV function result in 
developmental defects or lethality [149-152]. We reasoned that a method for SV 
isolation from cultured neurons would allow researchers to employ genetic engineering 
techniques ex vivo, including virus transduction, and to focus on specific brain areas 
or even specific neuronal populations. In two studies [147, 153], SVs were isolated 
from cultured neurons, which in one case had been transduced with a virus. However, 
the ability of the purified SVs to take up NTs was not demonstrated and details of the 
46 
 
experimental methodology, such as the amount of starting material or centrifugation 
protocols, were not disclosed. 
Here, we demonstrate that functional SVs are accessible from genetically 
engineered cultured cortical neurons in suitable amount for NT uptake and 
biochemical analysis. We showcase the introduction of an exogenous protein into SVs 
following this method by visualization of single SVs with TIRF microscopy. Collectively, 
these results demonstrate efficient modification of functional SVs using cultured 
neurons and viral genetic engineering, and open the door to new structural and 
functional studies of SVs in diverse contexts. 
 
 
3.3. Methods 
3.3.1. DNA constructs 
Ratio1XsypHy was a gift from Thomas Oertner and Tobias Rose and obtained from 
Addgene (#44268) [138]. Ratio1XsypHy was subcloned into a modified pLenti6.3/V5-
DEST vector (Thermo Fisher Scientific) between ClaI and XbaI restriction sites and 
expressed under the control of the human synapsin promoter 
(pLenti6.3::hsyn::Ratio1XsypHy). 
 
3.3.2. Lenti virus production (reproduction from chapter 2 with modifications) 
Lenti virus production and purification was performed as described previously [78]. 7.0 
x 106 Lenti-X 293T cells (Clontech) were seeded in Dulbecco’s modified Eagle’s 
medium (Life Technologies) supplemented with 10% v/v fetal bovine serum (FBS) in 
poly-L-ornithine (0.01% w/v, Sigma)-coated 15 cm cell culture dishes (Corning) and 
incubated at 37°C in a 5% CO2 atmosphere. After 15 h, medium was changed and 
cells were incubated at 37°C for 30 min. Cells were then transfected with 
pLenti6.3::hysn::Ratio1XsypHy, VSV-G and delta 8.7 packaging plasmids at a 1:1:1 
molecular ratio (total amount: 22.5 g per dish) with polyethyleneimine (Polysciences) 
in Opti-MEM I medium (Gibco). Medium was changed after 7 h. 40 to 48 h after 
transfection, supernatant was collected for centrifugation at 1,000 x g for 10 min 
followed by filtering (0.45 µm). For virus concentration, filtered supernatant was 
layered over a 10% v/v sucrose cushion (20% w/v sucrose in 1 M NaCl, 20 mM 
HEPES, 0.25 mM EDTA, pH 7.4) and centrifuged at 4°C for 1.5 h at 150,000 x g. 
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During the 2 to 4 separate centrifugation runs, pellets were consolidated, resuspended 
in culture medium (see below) and stored at 4°C. After centrifugation, concentrated 
virus was aliquoted into O-ring conical tubes, snap frozen and stored at -80°C. 
Physical titer was determined using a reverse transcriptase qPCR kit following the 
provider’s protocol (Genecopia). Each viral preparation was tested for functional 
expression with a dilution series in glass bottom 24-well plates containing 5.0 x 105 
cortical neurons/well. Expression was assessed daily 5 d after transduction using an 
EVOS FL microsope (Thermo Fisher Scientific). The virus concentration that produced 
the highest expression in morphologically healthy cells at day in vitro (DIV) 15 was 
then utilized for transduction of neurons in 15 cm dishes (see below). 
 
3.3.3. Primary cortical neuron culture 
Cortical neurons were prepared from batches of six P0-P1 pups of Wistar rats (Janvier 
Labs). Animal housing and tissue extraction were performed in accordance with 
national and European guidelines. Briefly, cortices were isolated from both 
hemispheres in Hank's balanced salt solution (supplemented with 2.5 mM HEPES, 35 
mM D-glucose, 4 mM NaHCO3, pH 7.4) by removing midbrain, cerebellum and 
olfactory bulb and clearing the meninges from the tissue. Cortices were minced with a 
razor blade and transferred between two 15 ml conical tubes. Dissociation was carried 
out using a papain dissociation system following the provider’s protocol (Worthington). 
Neurons were maintained following established protocols [79] with modifications. Cells 
were suspended in plating medium that consisted of modified Eagle’s medium 
supplemented with 10% v/v FBS, 0.6% w/v D-glucose, 6 mM GlutaMAX, 1 mM Na-
pyruvate, 100 U/ml penicillin and 0.1 mg/ml streptomycin. Cells were counted in a 
Neubauer chamber and 30 x 106 cells were seeded in each poly-L-lysine (PLL, 0.1% 
w/v, Sigma)-coated 15 cm cell culture dish. After 5 to 6 h, one volume of medium 
(Neurobasal-A, supplemented with 2% v/v B27 and 6 mM GlutaMAX) was added to 
each dish. At DIV2 to DIV3, medium was supplemented with 4 M cytosine β-D-
arabinofuranoside to reduce glial growth. Finally, cells were transduced with lenti virus 
during medium change at DIV5 and subsequently half of the medium was changed 
every 2 to 3 d. Neurons were typically transduced with 100 to 150 l of concentrated 
virus solution (0.5 to 0.75 x 109 viral particles/dish) and displayed robust expression 
at DIV15. 
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3.3.4. SV isolation 
3.3.4.1. Culture 
Neurons at DIV15 to DIV18 were washed twice with ice cold phosphate buffered saline 
(PBS). All steps were performed on ice or at 4°C. Homogenization buffer (0.32 M 
sucrose, 1 mM NaHCO3, 1 mM Mg-acetate, 0.5 mM Ca-acetate, cOmplete protease 
inhibitor cocktail (Sigma), pH 7.2) was added to a final volume of 5 ml per dish and 
cells were gently scraped off and pooled in a 40 ml Dounce tissue grinder (Sigma). 
Homogenization was performed manually with five strokes using pestle A (clearance 
0.0030-0.0060”) and 10 strokes using pestle B (clearance 0.0010-0.0030”). 
Homogenate was centrifuged for 15 min at 12,000 x g. Supernatant was discarded 
and the pellet was resuspended in lysis buffer (6 mM Tris-maleate, cOmplete, pH 8.1) 
and incubated for 45 min. The suspension was centrifuged at 44,000 x g for 15 min. 
The pellet was discarded and the supernatant was centrifuged at 200,000 x g for 55 
min. The pellet was gently dislodged with a Teflon-coated scraper and transferred to 
a 1.5 ml pre-chilled tube containing 200 to 400 l storage buffer (0.32 M sucrose, 1 
mM NaHCO3, cOmplete, pH 7.2) for resuspension. A small aliquot (20 l) was set 
aside for protein quantification. Dithiothreitol was added to the SV suspension to a final 
concentration of 1 mM and SVs aliquoted into pre-chilled O-ring conical tubes. 
Samples were stored either in liquid nitrogen for up to 1 yr [154] or snap frozen and 
stored for up to two weeks at -80°C. Aliquots of 200 l from the homogenization and 
lysis steps from all preparations were used for protein quantification and Western blot 
analysis. Protein amounts were quantified using a Pierce BCA protein assay kit 
(Thermo Fisher Scientific). 
For SV purification by a flotation gradient method [155, 156], neurons were 
homogenized as above in homogenization buffer (0.32 M sucrose, 10 mM Tris-HCl, 
cOmplete, pH 7.4). Homogenate was centrifuged for 10 min at 1,500 x g and 
supernantant was collected. The pellet was resuspended in homogenization buffer 
and centrifuged for 10 min at 1,500 x g. Supernatants were combined and centrifuged 
for 20 min at 20,000 x g. The pellet was resuspended in lysis buffer (5 mM Tris-HCl) 
for 45 min and then centrifuged for 20 min at 20,000 x g. The supernatant was 
collected and centrifuged for 45 min at 66,000 x g. The final pellet was resuspended 
in storage buffer (100 mM KCl, 10 mM NaCl, 1 mM MgCl2, 10 mM K-phosphate buffer, 
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cOmplete, pH 7.4) containing 50% OptiPrep solution (v/v, 1:1 ratio, Sigma) and 
overlaid with storage buffer containing 40% OptiPrep solution. The resultant gradient 
was centrifuged for 3 h at 207,000 x g. SVs could not be observed in the OptiPrep 
layers. The protocol was successfully tested on brain tissue (data not shown). 
 
3.3.4.2. Cortex 
A single hemisphere cortex was isolated from one P18-P21 Wistar rat. Midbrain, 
cerebellum and olfactory bulb were removed and tissue was minced with a razor blade. 
SV isolation from cortex was performed as described above using differential 
centrifugation and buffer volumes described in previous work [154]. 
 
3.3.5. Trichloroacetic acid (TCA) precipitation 
For each sample, the volume corresponding to 25 g SV protein was brought to a final 
volume of 400 l with water followed by addition of 100 l of ice cold TCA (50% v/v) 
and vortexing. Samples were incubated on ice for 60 min and then centrifuged for 5 
min at 4°C at 20,000 x g. Solvent was aspirated and replaced with 150 l ice cold 
acetone. The pellet was washed twice by inverting the tube and the centrifugation step 
was repeated. The acetone was aspirated and samples were incubated at 37°C for 1 
min to remove residual solvent. The pellet was resuspended in Laemmli buffer (40% 
v/v glycerol, 0.24 M Tris-HCl, 8% w/v sodium dodecyl sulfate (SDS), 0.04% w/v 
bromophenol blue, 5% v/v -mercaptoethanol) to a final concentration of 0.5 to 1 µg/µl. 
The pellet was then incubated for 20 min at 37°C and for 5 min at 95°C followed by 
equilibration to RT and centrifugation (11,000 x g for 1 min). Samples were analyzed 
directly or after overnight storage at -20°C. 
 
3.3.6. Western blot (WB) 
WB analysis was performed using SDS-polyacrylamide gel electrophoresis as 
described previously [157]. Briefly, 12.5 g precipitated protein was separated on 4-
20% Mini-PROTEAN TGX gels (BioRad) in duplicate. One replicate gel was stained 
with 0.25% w/v Coomassie Brilliant Blue R-250 in staining solution (10% v/v glacial 
acetic acid and 45% v/v MeOH) for 3 h, then destained overnight in staining solution 
and recovered in distilled water for 1 h before imaging. The second replicate gel was 
electroblotted onto a polyvinylidene difluoride membrane. Membranes were blocked 
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with 5% w/v milk powder in Tris-buffered saline supplemented with 0.1% v/v Tween 
20 for 1 h and incubated with primary antibodies against synaptophysin (dilution 
1:5000, #101002, Synaptic Systems) and glutamate ionotropic receptor NMDA type 
subunit 1 (GluN1) (dilution 1:1000, #114011, Synaptic Systems) in blocking solution 
overnight at 4°C. Secondary antibody (goat anti-rabbit IgG(H+L)-horseradish 
peroxidase (HRP) conjugate or goat anti-mouse IgG(H+L)-HRP, dilution 1:10000, 
#170-6515, #170-6516, Biorad) was applied for 1 h at RT. Blots were developed with 
Clarity Western ECL Substrate (Biorad). Blots and gels were imaged with an 
Amersham 600RGB Imager (GE Healthcare). Total protein content from Coomassie-
stained gels and levels of GluN1 and synaptophysin from blots were quantified in three 
biological replicates using Image Studio Lite software (LI-COR Biosciences). The level 
of GluN1 or synaptophysin per sample was normalized to total protein content of the 
respective duplicate lane. 
 
3.3.7. 3H-Glu uptake 
Uptake assays were carried out as described previously [158, 159] with modifications. 
SV were thawed on ice for 30 min. Amounts corresponding to 10, 25 or 50 µg of total 
protein were suspended in 100 µl storage buffer. 80 µl of preincubation (PI) solution 
(final concentration: 20 mM HEPES, 90 mM K-gluconate, 4 mM KCl, 2 mM aspartate, 
4 mM MgSO2, pH 7.4 adjusted with Tris base) was added and the samples incubated 
on ice for 30 min. Samples were transferred to a heat block shaker and incubated for 
10 min at 30°C and 500 RPM. 20 µl uptake solution (PI supplemented with 20 µM 3H-
Glu, Perkin-Elmer; specific activity 20 Ci/mmol, 1 mCi/ml) was added supplemented 
with either 2 mM ATP or water and incubated for 10 min at 30°C and 500 rpm. 
Reactions were stopped with 1 ml ice cold stop buffer (0.15 M KCl, 1 mM MgCl2) and 
samples were transferred to ice. Samples were then filtered on Millipore HAWP filters 
(0.45 µm, 13 mm diameter) loaded with 5 mM K-glutamate. Sample tubes were 
washed twice and each filter was subsequently washed with a total volume of 20 ml 
of ice cold stop buffer. Filters were allowed to dry before adding them to scintillation 
vials with 10 ml of scintillation buffer (Carl Roth). Vials were shaken for at least 24 h 
and briefly vortexed before measurement. Radioactivity was measured in a Tri-Carb 
2810 low activity liquid scintillation analyzer (PerkinElmer). Blank vials containing only 
the uptake solution were subtracted. 
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3.3.8. Antibody labeling and adsorption of SVs 
Glass coverslips (1.5H, Marienfeld) were placed into a home-made holder and 
immersed for 4 h in Piranha solution (3:1 H2SO4:H2O2; prepared by slowly adding 150 
ml of H2SO4 to 50 ml of 30% H2O2). The coverslips were washed 6 times in water and 
kept in water. On the day of imaging, coverslips were dried and placed in a plasma 
oven (Diener Electronic, 30 W setting) for 10 min. Imaging wells (5 mm diameter; [160]) 
were glued to the surface of the coverslip with optical adhesive (Norland) and dried 
under a UV lamp. Each well was coated with PLL (0.1% w/v) for 20 min, washed 3 
times with water and allowed to dry. 0.1 to 10 g of SVs were suspended in 50 l 
uptake solution and allowed to adhere for 1 h at 4°C before imaging or antibody 
labeling. For staining, SVs were blocked with 5% w/v bovine serum albumin (BSA, 
Sigma) in phosphate buffered saline (PBS) for 30 min followed by primary antibody 
labeling against vesicular glutamate transporter 1 (VGluT1) (dilution 1:1000, #135303, 
Synaptic Systems) for 30 min. Samples were washed 3 times with 5% BSA in PBS 
and incubated with secondary antibody (Abberior STAR RED, dilution 1:1000, #41699, 
Sigma) for 20 min. Finally, SVs were washed 3 times with uptake solution and 30% 
OptiPrep in uptake solution was added to each well 10 min before imaging. 
 
3.4.9. TIRF microscopy 
An Olympus IX83 microscope equipped with cell^TIRF module and Olympus UApo oil 
immersion objective (100 x, NA 1.49) was employed to image SVs in TIRF illumination. 
Excitation wavelengths were 561 and 640 nm for tdimer2 and STAR RED, resp. 
Images were obtained using a quad line beam splitter emission filter (Chroma) and a 
EM-CCD camera (Hamamatsu). Samples were imaged for 20 frames at 1 Hz. 
Colocalization analysis was performed in Image J using the ComDet plugin 
(https://imagej.net/Spots_colocalization_(ComDet)). Projections of the median 
fluorescence intensities of each time lapse were used for analysis to minimize non-
vesicle fluorescence. Colocalization was defined as the percentage of particles 
detected in the first channel that are also detected in the second channel. As an 
estimate for coincidental colocalization, one image was rotated 90° and reanalyzed 
(Fig. 3.2E). As a further control, images recorded from samples only treated with the 
secondary antibody were analyzed (Fig. 3.2E).  
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3.4. Results 
3.4.1. SV isolation from cortical neuron culture 
The goal of this work was to isolate SVs from cultured neurons that were transduced 
with lenti virus (Fig 3.1A). We chose cortical neurons because the cortex offers 
abundant starting material and because cortical neurons are a common ex vivo 
preparation and neuronal model system. As a first step, we estimated how much 
starting material will be required to isolate SVs for NT uptake and single SV imaging 
experiments. Between 20 and 60 g of SV preparation (total SV protein amount) are 
typically required for a single NT uptake experiment, whereas smaller amounts 
(between 1 and 5 g) are sufficient for WB analysis and single SV imaging [134, 135, 
144, 154, 158]. In previous work, 0.3 to 2 mg of SV protein amount were obtained 
from 1 g of adult rodent brain tissue (wet weight) depending on the isolation and 
purification procedure [154, 161]. 1 g of rat cortex contains 30 to 50 x 106 mature 
neurons with active synapses [2, 162]. Accounting for variability in culture activity and 
viability, we decided that plating a total 120 x 106 neurons in four 15 cm dishes (30 x 
106 neurons/dish) should provide sufficient SV material for uptake and imaging 
experiments in multiple conditions and with technical replicates.  
For SV isolation, we adapted a differential centrifugation protocol developed by 
Kish and Ueda for brain tissue [154]. We harvested neurons into homogenization 
buffer and isolated SVs from lysed synaptosomes (Fig 3.1A). We minimized the 
amount of solution employed during tissue harvesting, lysis and SV storage to ensure 
high final SV concentrations while maintaining sample solubility and homogeneity. To 
demonstrate enrichment of SVs, we probed samples at each step of the procedure for 
synaptophysin, a marker for SV membranes, and for GluN1, a marker for intracellular 
and plasma membranes (Fig 3.1B). We found a robust enrichment of synaptophysin 
and a robust reduction of GluN1 that is comparable to that observed for intact cortex 
samples (Fig 3.1B) and for brain in literature [163, 164]. The final yield was 0.53 ± 0.10 
mg total protein from one preparation consisting of four dishes. This result indicates 
that sufficient SV material for experiments can be obtained; however, the yield was 
somewhat lower than aforementioned estimate, which we attribute to differences in 
the activity and number of synapses in cultured neurons and intact cortex. 
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Fig 3.1 SV isolation procedure. (A) Cortical neurons are prepared from rat pups 
and transduced with lenti virus in culture. Cells are homogenized and SVs isolated 
from synaptosomes (SN). (B) WB analysis of a cell membrane marker (GluN1) and 
a SV marker (synaptophysin; syp) at each stage of the isolation procedure for 
cultured neurons and for cortex (H: homogenate; amount loaded: 12.5 g in each 
lane). Band intensities are shown normalized to total protein (error bars denote S.D., 
n=3). (C) 3H-Glu uptake for SVs isolated from cultured neurons and cortex 
(experiments were performed with 25 g SV protein; error bars denote S.D., n=3). 
 
 
 
SVs isolated using differential centrifugation from brain samples have in previous work 
been further purified using sedimentation velocity or sedimentation equilibrium 
centrifugation in density gradients. Although purification is not essential for functional 
experiments (see below and, e.g., [154, 158, 165]), we also tested if SVs isolated from 
cultured neurons are amenable to a gradient protocol that has been previously applied 
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to small SV sample amounts [147, 156]. However, we were not able to detect SV 
protein at the end of this protocol and focused on the robust differential centrifugation 
method. 
 
3.4.2. 3H-Glu uptake into SVs 
To verify functionality of SVs isolated from cultured neurons, we evaluated ATP-
dependent uptake of radiolabeled glutamate (3H-Glu). We found that 3H-Glu signals in 
the presence and absence of ATP were comparable for SVs isolated from cultured 
neurons and intact cortex (Fig 3.1C). Furthermore, the ATP-dependent signal increase 
for both preparations (e.g., for cultured neurons: 7.0  0.4 fold, mean  SD, n=3) was 
similar to that observed in previous work [154, 158]. These experiments were 
performed with 25 g SV protein. We found that lower amounts did not permit reliable 
uptake measurements (10 g: ATP-dependent increase was 3.1  0.6 and 3.2  1.3 
fold, for culture and cortex, resp., n=3), whereas higher sample amounts resulted in 
improved ATP-dependent increase (50 g: 13.2  0.7 and 14.1  1.1 fold for culture 
and cortex, resp., n=3 and n=5), as expected. These results demonstrate robust NT 
uptake function and allow us to propose a SV protein amount (25 g) that permits 
reliable uptake measurements in a manual filtration system. At this amount, at least 
four uptake experiments with technical replicates can in our hands be performed with 
the material obtained from one four-dish preparation. 
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Fig 3.2. SVs from genetically modified neurons. (A) Ratio1XsypHy is 
synaptophysin modified with pHlourin on the luminal side and tdimer2 at the far CT. 
(B) Ratio1XsypHy expression in cortical culture (DIV18). Left: bright field. Right: 
tdimer2. (C) 3H-Glu uptake into SVs isolated from transduced neurons (experiments 
were performed with 25 g SV protein; error bars denote S.D., n=3). (D) TIRF 
microscopy of SVs expressing Ratio1XsypHy (tdimer2 signal) stained against 
VGluT1 (STAR RED signal). (E) Co-localization analysis of Ratio1Xsyphy with 
VGluT1. 1: Colocalization of VGluT1-positive particles with Ratio1XsypHy-positive 
particles. 2: Colocalization of VGluT1-positive particles with Ratio1XsypHy-positive 
particles after image rotation. 3: Colocalization of Ratio1XsypHy-positive particles 
with VGluT1-positive particles in the absence of primary antibody. Error bars denote 
S.D., n=4-5. 
 
 
 
3.4.3. SVs from genetically engineered neurons 
To test the overall procedure, we went on to characterize SVs isolated from cortical 
neurons that were virally transduced to express an exogenous SV-localized protein. 
Fluorescently-tagged synaptophysins are commonly employed as genetically 
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encoded sensors for SV trafficking and fusion [153, 166, 167]. Ratio1XsypHy [138] is 
a dual-color synaptophysin-based sensor that contains pHlourin, a pH sensitive variant 
of GFP in the luminal domain between the transmembrane helix 3 and 4, and tdimer2 
[168], a red fluorescent protein tandem dimer at the cytosolic CT (Fig 3.2A). 
Ratio1XsypHy previously served to visualize SV trafficking (using the tdimer2 signal) 
and fusion (using increased pHluorin fluorescence upon SV deacidification). We first 
validated Ratio1XsypHy expression in cortical neurons after transduction with a lenti 
virus and under the control of the human synapsin promoter. We observed a punctate 
expression pattern that is typical for SVs and synaptophysin-based sensors in cultured 
neurons (Fig 3.2B) [169]. Next, we isolated SVs from the transduced neurons, verified 
ATP-dependent 3H-Glu uptake (Fig 3.2C), and established conditions for single vesicle 
imaging in TIRF microscopy. We chose TIRF microscopy due to its ability to sensitively 
and selectively visualize particles adhered to a surface. We found that adsorption of 
100 ng of SV protein in 5 mm imaging wells permitted visualization of individual 
Ratio1XsypHy-positive SVs (Fig 3.2D, left), whereas adsorption of 1 or 10 g produced 
comparable images that did not permit detection of single fluorescent particles (Fig 
3.3). To quantify the efficiency of SV modification, we stained SVs against VGluT1, a 
vesicular marker for glutamatergic neurons [170] (Fig 3.2D, right). We observed 
comparable numbers of fluorescent particles in the Ratio1XsypHy channel and in the 
VGluT1 channel (466  70 and 423  28, resp.; mean  SD, n=5). We further found 
that fluorescent signals from VGluT1 showed high colocalization with signals from 
Ratio1XsypHy, and vice versa, whereas both a confidence test (rotation of the 
Ratio1XsypHy image by 90°) and negative controls (secondary antibody only) 
exhibited poor colocalization (Fig 3.2E). The level of colocalization demonstrates 
robust viral delivery of a gene that encodes a SV-targeted protein to the cultured 
neurons and the overall efficiency of the method. 
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Fig. 3.3 TIRF microscopy of SVs expressing Ratio1XsypHy (tdimer2 signal) 
adsorbed at higher SV protein amounts. 
 
 
3.5. Discussion 
Experiments with isolated SVs from genetically engineered neurons have in the past 
generally relied on the availability of transgenic animals. This approach is constrained 
by cost, time and a limited ability to manipulate some of the key proteins involved in 
SV function because of developmental defects, lethality and compensation [149-152]. 
Collectively, these limitations may explain the relatively small number of studies that 
describe the structure or function of SVs after genetic modification [144, 147-149] 
despite continued strong interest in SV biology. 
Here, we demonstrate the isolation and characterization of SVs from genetically 
engineered cortical neuron cultures. Our results show that 120 x 106 cortical neurons 
processed by differential centrifugation provide sufficient SVs for functional 
experiments. SVs obtained from the cultured neurons showed comparable enrichment 
and reduction of marker proteins and ATP-dependent activity to reference 
preparations from cortex. We identified the lowest amounts for which reliable imaging 
and uptake measurements can be performed in our hands to be 100 ng and 25 g, 
respectively. These numbers indicate that multiple experiments with controls and 
technical replicates can be conducted using the material obtained from one 
preparation. We also demonstrated that manipulation of SVs in cortical neurons was 
efficient. 95% of the fluorescent particles that stained for a marker for SVs of 
glutamatergic neurons, which comprise the main neuron type in the cortex [171, 172], 
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also expressed the genetically introduced synaptophysin marker. In two previous 
studies, SVs were isolated from cultured neurons, which in one case were transduced 
with a virus [147, 153]. These studies did not disclose the amount of starting material, 
did not report SV function and employed a gradient-based method that could not be 
successfully applied to our cultured neuron samples. 
We anticipate that the ability to isolate functional SVs from genetically 
engineered cultured neurons will enable new combined in vitro and in situ studies. 
Isolated SVs are required as a starting material for a number of methods. These 
include quantitative, i.e. calibrated to vesicle number [133], ensemble biochemical and 
bioenergetics analyses (e.g. by WB or mass spectrometry) as well as single SV 
analyses (e.g. by advanced microscopy or fluorescence-activated sorting). These 
techniques can now be more readily applied to preparations from genetically 
engineered neurons, in which the levels of specific proteins are increased or 
decreased or in which proteins are modified with mutations or larger domain 
deletions/insertions. Chemically transfected cultured cell lines, e.g. rat 
pheochromocytoma cells, have in the past enabled the identification and 
characterization of SV proteins through the isolation of SV-like microvesicles [173, 
174]. These studies highlight further possible applications of genetically engineered 
neuron cultures, which are physiologically representative and can be obtained from a 
specific brain region or enriched in a specific neuron type. Overall, these studies will 
be facilitated by the growing availability and capability of gene delivery techniques, in 
particular engineered viruses, which can be tuned to selectively transduce specific cell 
populations with low toxicity or harbor cell-type specific promoters. 
A number of neurochemical properties and neurophysiological processes come 
to mind that may be studied by combining SV isolation, SV in situ analysis and genetic 
modification. These include revealing molecular determinants of different vesicle pools 
and their response to protein content perturbations, compensation in SV protein 
composition and variability between SVs, or the impact of post-translational 
modifications on SV protein function. Furthermore, the ability to introduce mutations 
may enable revealing molecular structure-function relationships of the vesicular 
proteins and their cellular binding partners that contribute to synaptic communication 
processes. In general, drawing parallels between SV content and function may 
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contribute to the identification of new drug targets and an understanding of existing 
and new disease models. 
 
 
3.6 Conclusions 
We demonstrate the isolation of SVs from genetically engineered cultured neurons. 
The function of the isolated SVs recapitulated the function of SVs obtained from intact 
cortical tissue. Genetic modification of SVs was efficient with high colocalization of an 
endogenous and an exogenous SV marker protein. Our work shows that SVs from 
genetically engineered neurons are accessible without the need for transgenic 
animals, and we anticipate that it will lead to new studies that draw parallels from in 
vitro and in situ analysis of SV content, structure and function. 
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Chapter 4: Towards Synthetic 
Neurotransmission 
 
I would like to thank Ingrid Chamma (Institute for Interdisciplinary Neuroscience, 
University of Bordeaux) for assistance with release assay imaging and Olivier 
Thoumine (Institute for Interdisciplinary Neuroscience, University of Bordeaux) for the 
use of his lab and equipment. This chapter contains unpublished data.
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4.1. Outlook 
In the previous chapters, I have shown that a Met-gated ion channel can be 
engineered for efficient gating and expression in mammalian cells and that cultured 
neurons can be transduced with lenti-virus to serve as a rapid test bed for assessing 
the function of SV proteins. Open questions towards the realization of synthetic 
neurotransmission (SNT) are, by what mechanism will Met be imported into the 
presynaptic neuron and further into SVs to achieve the goal of Met co-release, as well 
as, what experimental systems are in place to test SNT.  
It is well known that plasma membrane (PM) transporters of the SLC family, 
such as the L-type amino acid transporter type 1 (LAT1) are expressed in neurons 
[175-178].  LAT1 is a Na+-independent high-affinity transporter of large neutral amino 
acids, one of the primary transporters of Met [179, 180], and a necessary component 
for supplying neurons with Met for metabolic purposes [181]. LAT1 exhibits 
concentration based competitive transport of its substrates and elevation of Met is 
preferentially transported across the BBB and PMs [182] by monopolizing LAT1 as is 
the case for other known substrates, such as phenylalanine [179, 180, 183, 184]. To 
validate LAT1 expression and Met-uptake, I performed preliminary experiments in 
dissociated cerebellar granule cells (CGCs) and hippocampal neuronal culture (HNC) 
(Fig 4.1A). I found that immunolabeling against LAT1 showed high levels of expression 
both in CGCs and hippocampal neurons. I also found that Met-uptake in dissociate 
hippocampal culture is efficient (Fig 4.1B) and can be partially blocked with 2-
aminobicyclo[2.2.1]heptane-2-carboxylic acid (BCH), a specific inhibitor of L-type 
amino acid transporters. While there was a significant reduction in 3H-Met uptake with 
BCH, it remains unclear here to what extent other transport systems contribute to Met 
PM uptake. The sodium-coupled neutral amino acid transporters, like SNAT2 [185] are 
also expressed in neurons [186, 187] and catalyze unidirectional Met PM transport 
[187]. Immunostaining for SNAT2 in HNC and CGCs showed undetectable expression 
levels (data not shown); however, this may be more a problem of antibody efficiency 
than absence of protein, as SNAT2 has been shown to express in neurons elsewhere 
[186]. Therefore it is likely that the majority of Met uptake in neurons is a combination 
of SNAT2 and LAT1. This taken with LAT1 Met preference in a concentration 
dependent manner [179] shows that there are most likely sufficient endogenous 
systems in place for Met PM uptake and thus suit the purposes required here. A more 
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intensive pharmacological experimental paradigm (e.g. increasing the range of Met 
transporter blockers) in a pure neuronal culture (e.g. Banker’s culture) [188] would be 
required to determine specific concentrations of Met uptake in neurons.   
 
 
 
 
Fig 4.1. LAT1 facilitates Met uptake in neurons. (A) Immunolabeling against LAT1 
(rabbit anti-LAT1, 1:200 dilution, Santa Cruz biotechnologies  #F0414, secondary 
antibody 1:500 dilution, 488 AlexaFluorTM goat-anti-rabbit, antibody labeling was 
performed as described in chapter 2). (B) Radiolabeled Met uptake in HNC as 
described previously [189] with modifications. Briefly, cells were cultured as in 
chapter 2, washed once with warmed PBS and incubated in sodium buffer (140 mM 
NaCl, 5 mM KCl, 5.6 mM D-glucose, 0.9 mM CaCl2, 1 mM MgCl2, and 10 mM 
HEPES, pH 7.3) containing 3H-Met  (supplemented with cold Met  at a ratio of 
1:1000) with 1 mM BCH (diamonds) or without (circles). Uptake was stopped by the 
addition of 3x wash with ice-cold sodium buffer and lysed in 1M NaOH. Lysate was 
diluted in scintillation buffer and tritium counts were read (see chapter 3). Uptake 
experiments were performed at 37°C. Error bars denote ± SD., n = 2, for each n 
conditions were run in duplicate.  
 
 
Whereas PM uptake of Met is enabled by members of a transporter families that are 
expressed ubiquitously, such transport systems do not exist in SVs.  
Neurotransmitter (NT) identity is a feature of all neurons because it delineates 
the type of information conveyed. While the general assumption is that classes of 
neurons release a singular NT, exceptions continue to amass. The concept of co-
release has gained recent traction with the discovery dual NT species released from 
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neuronal types previously thought to be NT specific [190]. It has been previously 
reported that SVs have the ability to load multiple NT species [190-192], and  there is 
evidence that a singular SV contains dual transporters, as in the case of VGluT2 and 
VMaT2 [193, 194]. Variants of monoamines, as in the case of false fluorescence 
neurotransmitters [195] and non-selective uptake of stereoisomers of glutamate [53] 
have been shown to package into SVs. In the case of Met, which share the same zero-
charge as Dopa and GABA [196], taken with the above, it is reasonable to hypothesize 
dual SV filling of Met through a synthetic VT may be well tolerated.  
I thus identified candidate proteins for the role of a vesicular Met-importer 
(Table 4.1). These transporters are primarily microbial exporters, part of the Amino 
acid-Polyamine-organoCation superfamily [197] that thus may transport Met into SVs.  
Two of the transporters have been characterized in their native system and were 
shown to be powered by proton gradients (and thus harness the natural import driving 
force in SV NT packaging) [198, 199]. One candidate is a high affinity Met permease 
from yeast (see Table 4.1) that is solely concentration dependent uptake. These 
candidate transporters carry the added advantage in they rely on them as single 
genes, unlike the high affinity Met transport systems found in many prokaryotic species 
which relies on a multiple gene expression for functionality, such as brnFE genes in 
a C. glutamicum strain [200] or the E. coli MetD system [201]. In addition to and in line 
with the above, it is important to note that, at least for glutamatergic synapses, which 
are a first choice for this method, I do not expect that the expression of additional 
transporters in SVs will alter loading of the endogenous neurotransmitter as it was 
previously shown that more transporter means more Glu, i.e. H+ gradient are not 
exhausted [202]. To target these non-mammalian proteins to SVs, I have designed a 
repurposed syn gene. One set of the candidate transporters were directly inserted 
between the 3rd and 4th helices of the Ratio1Xsyphy construct used in chapter 3, the 
other set of transporter candidates an additional helices was inserted after the 
transporter gene, for correct transporter orientation in the SV membrane (Fig 4.2A). 
This design has proven to be an effective targeting strategy for prokaryotic proteins 
targeted to mammalian SVs [57]. I refer to these constructs as vesicular methionine 
transporters (VMetTs).  For VMetT candidate 1 (VMetT1) delivered into hippocampal 
neurons, I was able to show that trafficking is directed to pre-synaptic structures with 
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microsopy (Fig 4.2 B,C) and a stimulated release assay revealed functional fusion 
events (Fig 4.2 D) 
 
 
 
 
Fig 4.2. Targeting prokaryotic methionine transporters to SVs (A) Design of 
targeting strategy. (B) Hippocampal axon in dissociated culture expressing VMetT1 
(B, Upper panel confocal) (scale bar denotes 10 μm). STED images of VMetT1 (B, 
left), VGluT1 (center left), Tau (center right) overlay image (far right) shows 
localization within an axonal bouton (scale bars denote 1 μm). (C,D) High potassium 
stimulation reveals release events.  Histogram of fluorescence intensity (green 
channel) for three identified boutons expressing VMetT1.  
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A system such as SNT, designed to synthetically connect two distinct sub-
cellular populations, must first be broken down to its individual parts and characterized 
separately.  The final step in proof of concept is therefore bringing these components 
back together in a system that can easily identify successful SNT.  An experimental 
system that fits these requirements well is co-culture, culturing two populations of cells 
that distinctly express proteins of interest [79].  Creating simplified PSDs by expressing 
base unit proteins, like neuroligins and membrane-associated guanylate kinases in 
cell lines, create faux synapses when cultured at defined time points with a wide variety 
of neuronal types and can be used extract information about protein dynamics in 
synaptic interactions [203, 204]. I established this system to show that channel 
activation can be observed in a synapse specific manner (Fig 4.3).  
 
 
Fig 4.3. Neuron-HEK 293 co-culture (A) Representative paroxysmal currents from 
CGCs in whole cell gap free mode with application of Mg+2 free bath solution.  (B) 
HEK 293 cell expressing neuroligin-1 CT tagged with eGFP in TIRF (100x). (C) 
Representative paroxysmal currents in HEK 293 cells expressing neuroligin1, PSD-
95, and NMDAR subunits 1-1a and 2A, transfections were carried out as in chapter 
2.  Currents were elicited with application of Mg+2 free bath solution and could be 
eliminated with D-AP5 (specific NMDAR inhibitor) or inclusion of Mg+2 in the bath 
solution. (D) Comparison of total charge elicited from faux synapse in HEK 293 cells 
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in gap free whole cell patch clamp under various conditions.  All experimental 
procedures were carried out as previously describe [203]. Error bars denote ± SD., 
scale bars represent 0.1 nA and 10 s. 
Viral targeting of VMetTs to a dissociated neuronal culture (chapter 3) in 
conjunction with a cell line expressing iMetR tagged PSD-95 complexing variants 
(chapter 2) to create a faux synapse would allow electrophysiological or calcium 
imaging experiments to be performed with ease (e.g. no additional blockers to isolate 
iMetR current) and provide valuable insight into Met-iMetR dynamics across synapses 
in a SNT fashion. 
 
 
4.2. Discussion 
Biological methods created to study components of neuronal communication by 
targeting one neuronal type en masse have in recent years aided in the dissection of 
genetically define circuits. While much of this ground is covered by the advent of 
optogenetics and chemogenetics there is still much left to be desired. As with any tool, 
understanding the limitations or possible negative consequences that may arise from 
the implementation or use of that tool is critical information and worth addressing.   
Readily used chemogenetic tools like DREADD (metabotropic) [205] and 
PSEM/PSAMs (ionotropic) [50] have faced application based challenges. DREADDs 
have come into orthogonality conflict with the preferred designer ligand CNO, which 
has been recently shown to be BBB impermeable [206], rather its metabolite, 
clozapine, a well-known anti-psychotic, readily crosses the BBB instead.  This shift in 
designer ligand, while a much more potent activator of DREADDs, may cause un-
specific activation of native receptors, which may be masked by larger synthetic 
signals inside the region of interest or unobserved, due to activation outside of the 
observed region of interest.  Unlike the case of CNO-clozapine, Met is readily taken 
up by the BBB and while metabolites of Met like homocysteine, have been shown to 
cause toxicity at only very high levels [207, 208], the Met metabolic cycle important for 
homeostatic regulation of homocysteine levels is an effective endogenous counter-
measure, and in fact acute increases in Met have been shown to carry neuroprotective 
properties (see chapter 2). In the case of PSEM/PSAM, prolonged durations of PSEMs 
for excitatory overrides due to inefficient ligand clearing may lead to excitotoxicity.  
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Unlike the PSEMs, housekeeping of elevated levels of Met may overcome undesired 
excitotoxicity. More globally, a major challenge for any biological method is controlling 
the amount of non-native protein levels while still producing the desired outcome. 
Overexpression of any exogenous protein may compete for space with native proteins 
[209] or change intrinsic membrane properties [210] both of which intrinsically alter the 
focused behavior intended to modulate; this can be countered by decreasing the level 
of introduced protein by integrative virus and promoter strength ex vivo and genetic 
models in vivo. 
To conclude, I have introduced methods and components towards realizing a 
SNT system. Our aim with SNT is to provide a method that allows researchers the 
ability to manipulate the analog signals of a predefined post-synaptic target by 
designated pre-synaptic digital output, using the power of the natural signaling 
machine of the pre-synapse.  This is of great value for three major reasons.  The first 
being, all divergent and convergent information coming from upstream and/or 
collateral targets is preserved.  Second, targeting a specific synaptic type 
(glutamatergic versus GABAergic) will allow subcellular dissection of the importance 
of that synaptic pair on the analog computation of the post-synaptic target and third, it 
is well know that the breakdown of communication between neuronal types that lead 
to severe neurological disorders (like Parkinson’s or Alzheimer’s) is not binary or 
immediate, rather it is a slow degenerative process and a system which one could 
modulate subcellular connectivity would be of great value in understanding the onset 
of neurological disorders. Off target effects can be difficult to side step or eliminate 
completely, especially if they are not paired with electrical observation or simply too 
subtle at first to be observed yet amplify overtime with repeated exposure of light or 
ligand. One other advantage of a SNT system is that any gain of function can be pin 
pointed back to the original source of modulated synapses. In order to understand in 
greater detail the causal link between the analog to digital conversion in cell-cell 
communication and behavior in health and disease, the concerted application of 
current tools such as genetic manipulation (e.g. transgenic animal models such as 
MADM [211]), electrical monitoring (e.g. implantable electrodes), and high resolution 
imaging (e.g. endoscopic and multi-photon imaging [212]) in vivo with biological 
systems, like SNT, will generate new data sets and will bring new insights to the causal 
relationships in the mammalian brain. 
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Table 4.1 Candidate Met Exporters 
Name Gene Function Driving force Organism Uniprot ID/ACCESSION Source  Predicted helcies 
VMetT1 Yeas Met/Leu exporter 
electrochemical 
gradient 
Escherichia coli P76249  [198] 6 
VMetT2 Yjeh Met exporter 
electrochemical 
gradient 
Escherichia coli P39277  [199] 11 
VMetT3 Yeas Homolog 1 unknown unknown 
Chromobacterium 
violaceum 
WP_011137350.1 n/a n/a 
VMetT4 Yjeh Homolog 1 unknown unknown 
Chromobacterium 
violaceum 
WP_011136979.1 n/a n/a 
VMetT5 Yeas Homolog 2 unknown unknown 
Desulfovibrio 
magneticus 
WP_006921580.1 n/a n/a 
VMetT6 Yjeh Homolog  unknown unknown Vibrio harveyi WP_017188716.1 n/a n/a 
VMetT7 MUP1 Met permease 
concentration 
gradient 
Yeast P50276 [213] 10 
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